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 Summary  
Mesenchymal stem cells thanks to their differentiated multipotent ability are 
considered the most promising candidate for tissue engineering and regenerative 
medicine. The source of mesenchymal stem cells up to about 20 years was 
represented by the bone marrow, but due to their limited amount of cells together 
with a very invasive and painfull surgical treatment,  poorly accepted by patients, has 
led the scientific community to investigate an alternative mesenchymal stem cells 
source with similar properties. In particular, the adipose tissue has attracted the 
greatest interest thanks to its relative abundance, the easy of availability and the large 
amounts of mesenchymal stem cells which are obtenible. So this adipose stem cells 
subpopulation, once verified the same differentiation potential of them derived from 
bone marrow, represent the ideal type of adult mesenchymal stem cells useful for 
numerous regenerative and tissue engineering applications. In particular the bone 
regeneration, obtained after the lipotransfer of a specific stem cells subpopulation 
isolated from adipose tissue, should be considered one of the most successful 
applications in the field of regenerative medicine and tissue engineering.  (Chapter 
1). A further widespread use of mesenchymal stem cells is to reconstructive medicine. 
In particular, most patients with breast cancer, whenever possible, based on the type 
and stage cancer disease (Chapter 2), first make use of a demolitive surgery, in order 
to completely remove the tumor mass presence, and then resort to a reconstructive 
plastic surgery procedure. In breast cancer patients it is often used the adipose tissue 
as autologous filler. Even though the surgical treatment does not represent a potential 
danger for the patient, many scientific works have highlighted how the use of these 
self transplantations constitute a great risk for a possible cancer relapse despite the 
absence of a minimal residual disease. The presence of a mature adipocytes 
population infact, is responsible of a specific microenvironment, composed by pro-
inflammatory cytokines and paracrine signals, that induce a generalized inflammatory 
state and which stimulate a proliferative return of those few quiescent cancer cells 
that still remain in the implantation site. In particular we have seen that the action of 
adipokines and interleukins generated by adipose autologous filler works both on 
differentiated tumor cells, just in a active proliferation cell phase but also on the 
cancer stem cell population that instead reside in a quiescent cell cycle phase. 
(Chapter 3). Therefore it is essential develop a more accurate and specific lipofilling 
procedure, especially going to select an appropriate autologous filler, in which a 
particular adipose stem cell subpopulation, with great regenerating properties has to 
be chosen among the adipose populations already present in conventional fillers. 
(Chapters 4). So the goal of this study is to enable the development of new selective 
therapies useful to remove the cancer stem cells, real responsible for tumor relapse. 
One of the most promising cancer therapies among those currently in the testing 
1
phase could be the differentiative therapy, and specifically one that uses the negative 
regulatory properties of the miRNAs (Chapter 5). 
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Abstract
Introduction: Adipose tissue represents an abundant source of 
mesenchymal stem-like cells. Adipose-derived stem cell progenies 
have been investigated and used in regenerative medicine for decades. 
In the last few years, they have been used to “enrich” lipoaspirates in 
fat grafting techniques, in an attempt to boost the regenerative potential 
of adipose tissue when used as autologous “filler”.
Materials and Methods: 50 adipose tissue samples from 
lipoaspirates and subcutaneous breast tissue biopsies were used to 
generate adipose floating spheroid cell (ASphC) lines. ASphC were 
characterized for the expression of putative mesenchymal stem 
cell markers and used in vitro to test their multilineage potential. 
Furthermore, ASphCs were seeded on dermal regeneration 
template (Integra®) and implanted into the T8 vertebral laminectomy 
site of immunocompromised mice. 
Results: Here, we show that the majority of ASphCs are in a 
quiescent state and express the putative surface stem cell marker 
CD271. Unlike CD271- cells, CD271+ ASphCs grew indefinitely in 
vitro as undifferentiated spheres in serum-free medium, maintaining 
their multilineage differentiation potential ability. Importantly, p107, 
a functional adipose stem cell marker, is strictly expressed in 
ASphCs and barely present in their differentiated mesenchymal 
lineages. These sphere cells display an enhanced ability in vitro 
to differentiate into distinctive end-stage cell types, such as 
osteoblasts, chondrocytes and adipocytes. Gene expression 
profiling analysis indicated that ASphCs are endowed with stem cell 
potential that is gradually lost during specific differentiation. Finally, 
ASphCs facilitate bone inter body repair and regeneration after 
laminectomy.
Conclusions: We conclude that ASphCs possess a pronounced 
in vivo activity to regenerate the bone injury. Overall, ASphCs 
represent a heterogeneous population of stem-like cells harbouring 
multilineage differential potential and representing a prospective 
promising tool in cell therapy and tissue engineering. 
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Introduction
Mesenchymal stem cells (MSCs) are considered to be important 
and promising candidates with regard to tissue engineering and their 
applications as regenerative medicine. This is largely due to their 
multipotent differentiation ability as well as their immunosuppressive 
properties [1,2]. The main characteristics of MSCs were first described 
in bone marrow tissue [3]. MSCs have been used with varying 
degrees of success in treating neurological, cardiovascular and 
hematopoietic disorders as well as other related diseases [4]. MSCs 
can also be isolated in minimal quantities from other tissues among 
which liver, synovium, skeletal muscle, peripheral blood [5]. Over the 
last 15 years, however, regenerative medicine research was focused 
on finding an abundant valuable alternative source of multi-potent 
stem cells [6,7]. It is known that bone marrow represents a suitable 
source of mesenchymal stem cells, which are used routinely in clinical 
applications associated with hematopoietic transplantation, revealing 
a promising alternative source for further development in regenerative 
medicine [8,9]. However, the difficult accessibility and low volumes of 
tissue obtained ex vivo, limit the clinical use of bone marrow-derived 
stem cells. Their harvest requires a painful procedure (iliac crest or 
sternal tap), neither of which is free from complications and overall, 
with a low compliance of the patients. Recent studies have shown that 
mesenchymal stem cells derived from adipose tissue can differentiate 
into a variety of cell lines (cardiomyocytes, myocytes, neurons, 
adipocytes, osteocytes, chondrocytes) [10,11] and improve the neo-
vascularization of ischemic tissue in limbs [12,13]. Adipose tissue is 
Growth Factor; BMP: Bone Morphonegic Protein; BRAF: 
Serine/Threonine-Protein Kinase B-Raf; DMEM: Dulbecco’s 
Modified Eagle’s Medium; EGF: Epidermal Growth Factor; 
FBS: Fetal Bovine Serum; FITC: Fluorescein Iso Thio Cyanato; 
GAPDH: Glyceraldehyde 3-Phosphate Dehydrogenase; H&E: 
Hematoxylin and Eosin; HRP: Horseradish Peroxidase; KRAS: 
K-Ras oncogene is a member of the Ras gene family; MSC: 
Mesenchymal Stem Cells; MTS: 3-(4,5-dimethylthiazol-2-Yl)-5-
(3-Carboxymethoxyphenyl)-2-(4-Sulfophenyl)-2H-Tetrazolium; 
NBT: Nitro-Blue Tetrazolium chloride; NP40: Nonidet P-40; NRAS: 
N- oncogene is a member of the Ras gene family; NSG: Non-
Obese Diabetic Severe Combined Immunodeficiency Gamma 
Mice; OPN: Osteopontin; PBS: Phosphate Buffered Saline; PE: 
Phycoerythrin; PFA: Paraformaldehyde; PI3K: Phosphatidylinositol-
4,5-Bisphosphate 3-Kinase; POU5F1: POU Class 5 Homeobox 1; 
PPARγ: Peroxisome Proliferator-Activated Receptor Gamma; Rb: 
Retinoblastoma; RUNX2: Runt-Related Transcription Factor 2; 
SCM: Stem Cell Medium; SD: Standard Deviation; SDA: ASphC-
Derived Adipocytes; SDC: ASphC-Derived Chondrocytes; SDO: 
ASphC-Derived Osteoblasts; SDS: Sodium Dodecyl Sulfate; 
SHAM: Placebo Surgery; SOX2: SRY Sex Determining Region Y 
Box2; SOX9: SRY Sex Determining Region Y Box 9; TP53: Tumor 
Protein P53; VEGF: Vascular Endothelial Growth Factor; WAT: 
White Adipose Tissue
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considered an ideal source of MSCs in association with therapeutic 
needs, since their isolation is achieved by means of a minimal invasive 
surgery [14,15]. Liposuction is a safe and non-invasive procedure. It 
is routinely performed through a 2-3 mm skin incision, well-accepted 
by patients who normally undergo this procedure for cosmetic 
reasons [16,17]. Approximately 5×103 adipose-derived stem cells are 
contained in 1 gram of adipose tissue, approximately 500 times more 
than those retrieved from bone marrow, of which only 0.01–0.001% 
of nucleated cells present in its structure, are MSCs [18,19]. The aim 
of this study is to enhance regenerative processes through the use of 
autologous mesenchymal stem cells. Adipose tissue can be discerned 
into three main categories: the visceral and subcutaneous anabolic 
white adipose tissue (WAT) that stores excess energy, the catabolic 
brown adipose tissue (BAT) which is responsible of dissipation of 
energy through heat production, and “Brown and White” (brite or 
beige) adipose tissue. WAT is typically related to obesity given that 
it refers to both, adipose cell hypertrophy or their hyperplasia from 
committed progenitors. Whereas, BAT fat cells are highly oxidant 
with abundant mitochondria that oxidizes fatty acids and generate 
heat [20,21].
One of the master regulators of adipocyte lineage is p107, a 
member of the retinoblastoma protein (Rb) family, which was 
reported to be strictly expressed in white adipose stem cells, down-
regulated during commitment toward the brown adipose lineage [22]. 
In particular, human adipose stem cells show high p107 expression 
levels, that progressively disappear after 7 days of differentiation 
[23,24].
Although it has been reported that human adipose-derived cells 
can be grown and expanded in serum-free medium as floating spheres 
harbouring a multilineage differentiation mesenchymal capacity [25], 
little is known about their phenotypic and molecular characterization. 
Several markers such as CD9, CD29, CD44, CD90, CD105 and CD271 
were suggested to be implicated in the identification of adipose 
mesenchymal stem cells equipped with a pronounced self-renewal 
ability [18,26]. Nowadays, a unique marker that identifies adipose cells 
with stem cell features is still unknown. In recent years, there has been 
a considerable evolution in our understanding of the mechanisms 
underlying tissue regeneration by MSCs [11]. The current applicability 
of mesenchymal stem cells in regenerative medicine seems to be 
limited by the combinatorial use of specific adjuvants molecules 
(cytokines and growth factors) for specific lineage differentiation (i.e. 
the use of BMP-2 for bone formation promotion [27], and kartogenin 
for chondrocyte differentiation induction [28]). An innovative 
approach in the field of regenerative medicine consists in the use of 
biocompatible scaffolds in combination with living cells for damaged 
tissue repair [29]. Here we show that the majority of adipose sphere 
cells (ASphCs) express CD271, necessary for the differentiation 
toward adipogenic, chondrogenic and osteogenic lineages. This 
cell compartment shows an enhanced in vivo regeneration ability 
especially when sphere cells are seeded on a dermal regeneration 
template (Integra®), suggesting a future prospective in cell therapy.
Materials and Methods 
Adipose tissue samples
Adipose tissue was extracted from a lipoaspirate and subcutaneous 
breast tissue biopsy of 50 patients (16 males; 34 females) in compliance 
with our Department’s policy and following patient’s written consent 
on adipose tissue harvest and its use for research purposes. Patients 
ranged from 20 to 65 years of age and all selected donors were healthy 
and without a prior history of malignancy. Tissues were obtained 
either from subcutaneous adipose tissue or during liposuction of 
the abdominal or inner thigh regions using Coleman’s cannulas, 
following infiltration with Klein’s solution (NaCl 0.9%; lidocaine 
2%; epinephrine 1:1000; NaHCO3 8.45%). Approximately, 20 cc of 
lipoaspirate and 0.05±0.02 gr tissue biopsies were collected from each 
patient and directly transferred to tissue culture tubes for enzymatic 
digestion and stem cell purification.
Cell isolation and culture
Breast-derived adipose tissue and lipoaspirate samples were 
digested with collagenase (1.5 mg/ml, GIBCO) and hyaluronidase 
(20 mg/ml, Sigma) through gentle agitation for 30 minutes at 37°C. 
The digested sample was centrifuged at 1200 rpm for 5 min and 
the recovered cells (Freshly) were plated with serum-free stem cell-
specific media as previously described [30]. Cells were plated in stem 
cell medium in presence of bFGF (10 ng/ml, Sigma) and EGF (20 ng/
ml, Sigma), in ultra-low adhesion tissue culture flasks (Corning) and 
placed at 37°C in a 5% CO2 humidified incubator. In these conditions, 
cells grew as floating spheroids (ASphCs). Part of the isolated cells 
were plated in adherent conditions (DMEM+FBS 10%) and were 
referred as primary culture (Primary). Conversely, we termed 
ADSCs the commercially available STEMPRO® Human Adipose-
Derived Stem Cells, plated as recommended by the manufacturer 
(Invitrogen). To evaluate ASphC multilineage differentiation capacity, 
5×103 single cells were diluted 1:4 in a cold Matrigel solution (growth 
factor reduced BD). This solution (50 µl/well) was dispensed into pre-
warmed 24-wells plates and let polymerize for 30 minutes at 37°C. 
Finally, the wells were filled using 700 μl/well of basal culture medium.
In order to classify adipose spheres as small, medium and large, 
cells within spheres derived from abdomen, hips and breast adipose 
tissue, were cytospun, fixed with 2% paraformaldehyde, permeabilized 
with 0.1% Triton X-100 (Sigma-Aldrich), and exposed to Toto3 
iodide (642/660, Invitrogen). Nuclear immunofluorescence analysis 
was detected by confocal laser-scanning microscopy. Counting was 
performed blinded by two independent observers.
Flow cytometry
Cells were stained with conjugated antibodies against CD44-FITC 
(G44-26, mouse IGg2bk, BD), CD271-ALEXA FLUOR 647 (C40-145, 
mouse IgG1k, BD), CD90-PE (5E10, mouse IgG1k, BD), CD45-FITC 
(5B1, mouse IgG2a, Miltenyi), CD19-ALEXA FLUOR 488 (HIB19, 
mouse IgG1k) or with purified primary, CD29 (MAR4, IgG1k, BD), 
CD73 (AD2, mouse IgG1k, BD), CD9 (ML13, mouse IgG1k, BD). 
Then, cells were labeled with goat anti-mouse IgG FITC secondary 
antibody (Invitrogen). Specific corresponding isotype matched 
antibodies were used as negative controls. Samples were acquired 
using a FACS ARIA (BD Biosciences) flow cytometer. All data were 
analyzed using FlowJo software (Tree Star).
Gene expression
Total RNA was extracted by using a RNeasy Mini Kit (Qiagen) 
and 1 µg of each sample was retro-transcribed into cDNA using a 
high-Capacity cDNA Reverse Transcription Kit as recommended 
by manufacturer (Applied Biosystems). Real-Time PCR reactions 
were performed with Two-Step RT-PCR TaqMan Probes (Applied 
Biosystems) using this primer set: Hs00765700_m1 (RBL1) (Applied 
Biosystems). The relative quantification of gene expression was 
calculated on triplicate reactions using the comparative Ct method 
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(ΔΔCt). Experimental target quantities were normalized with the 
endogenous Hu GAPDH control (Applied Biosystems). Expression 
of mesenchymal stem cell genes was performed through RT2 profiler 
PCR array (PAHS-082ZR, Qiagen), according to manufacturer’s 
instructions. Arrays were performed for ASphCs, ADSCs and their 
differentiate cells. At least 2 replicates were run for each sample.
Cell cycle and proliferation assay
Cell cycle analysis was performed on dissociated cells by 
staining with 50 µg/ml propidium iodide (Sigma-Aldrich) 
dissolved in buffer 0.1% sodium citrate (Sigma-Aldrich), 0.1% 
Triton X-100, 10 µg/ml RNAse (Sigma-Aldrich) for 1h on ice. 
Samples were acquired through a FACS Calibur flow cytometer 
(BD Biosciences).
The proliferation assay was evaluated by using PKH26 dye (Sigma-
Aldrich). 20×104 of dissociated cells were stained for 1 h at 37°C 
with PKH26 according to manufacturer’s instructions, then washed 
extensively with PBS and cultured for 14 additional days. PKH26 red 
fluorescence was analyzed by FACS Aria flow cytometer. All data were 
analyzed using FlowJo software.
Evaluation of ASphC and ADSC proliferation was assessed using 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) 
according to the manufacturer’s instruction.
Western blotting
Cells were re-suspended in ice-cold NP40 lysis buffer and 
fractioned on SDS-polyacrylamide gels and blotted on nitrocellulose 
membranes, as previously described [31]. Membranes were exposed 
to specific antibodies for p107 (C-18, rabbit IgG, Santa Cruz 
biotechnology) and β-actin (JLA20, mouse IgM; Calbiochem) and 
detected using HRP conjugated anti-rabbit or anti-mouse antibodies 
(Amersham). Chemioluminescent detection of protein expression 
was performed by Amersham Imager 600.
Osteogenic differentiation
Briefly, ASphCs and ADSCs were trypsinized 1 min at 37°C and 
plated into 24-well cell culture plates (50,000 cells/well). Cells were 
allowed to adhere and cultured in the STEMPRO® Osteogenesis 
Differentiation Kit (Invitrogen) up to 28 days. Cell viability, adhesion 
and differentiation were assessed by daily observation using an optical 
microscopy. Osteogenic differentiation was assessed by performing 
a staining for alkaline phosphatase activity (ALP) (BCIP/NBT 
alkaline phosphatase substrate kit, Vector Laboratories), osteopontin 
(OPN) (polyclonal rabbit, Sigma-Aldrich) or von Kossa for calcium 
deposition (Polysciences Inc.).
For ALP, cells were fixed in 80% methanol/20% citrate for 1 
minute and then stained in the dark at room temperature for 2 hours. 
For OPN detection and von Kossa staining see below.
Chondrogenic differentiation
Cells were allowed to adhere and cultured in the STEMPRO® 
Chondrogenesis Differentiation Kit (Invitrogen) up to 28 days. 
Chondrogenic differentiation was assessed by alcian blue. Briefly, 
the sample was fixed in 2% PFA for 30 min at 37°C, washed in PBS 
and incubated with alcian blue for 30 minutes. Cells were then 
counterstained with nuclear fast red for 5 minutes.
Adipogenenic differentiation
Cells were allowed to adhere and culture in the STEMPRO® 
Adipogenesis Differentiation Kit (Invitrogen) up to 28 days. 
Phenotype change was assessed by adipored assay (Lonza) for 10 min 
at room temperature. Nuclei were counterstained with Toto3 and the 
staining was observed using a confocal microscope.
Animal model
NSG mice were purchased from Charles Rivers Laboratories 
(Milan, Italy) and maintained according to University of Palermo’s 
institutional guidelines for animal care and use committee 
in animal house authorized by the Italian Ministry of Health 
(DGSAF#0020301-P-03102014).
In vivo laminectomy procedure was performed at the T8 vertebral 
level under aseptic conditions. 5×103 ASphCs and ADSCs, were 
seeded on 1 cm2 of dermal regeneration template (Integra®) for 4 
days in presence of SCM and then implanted into lesion whose the 
mice were subjected. Integra® (Integra Lifesciences Inc., Plainsboro, 
USA) is a bi-laminar skin replacement which comprises a layer 
composed by bovine collagen and shark glycosaminoglycans that 
facilitate the regeneration and a second layer composed of a synthetic 
polysilicoxane polymer that acts as a scaffold matrix. 
After 60 days the Integra® and the surrounding bone were 
harvested, fixed, paraffin-embedded and sectioned in order to 
evaluate the bone regeneration.
Five-uM thick paraffin-embedded sections were heated with 
antigen retrieval in 10 µM sodium citrate (pH 6.0). After have been 
incubated for 5 minutes with 3% H2O2, sections were permeabilized 
for 10 minutes with 0.2% Triton X-100 in PBS on ice. Sections were 
exposed overnight at 4°C to a specific antibody for OPN (Sigma 
Aldrich) or isotype-matched control at appropriate dilutions. 
Subsequently, sections were exposed to biotinylated immunoglobulins 
and streptavidin-peroxidase following manufacturers’ instructions 
(LSAB2 Kit, Dako). Staining was revealed using 3-amino-9- 
ethylcarbazole (AEC) substrate (red colour) and counter-stained with 
aqueous hematoxylin (blue color). The OPN positivity was calculated 
by observing at the red color staining and counting the percentage 
of positive cells in the regeneration area. Counting was accomplished 
blinded by two independent observers on four different areas per 
sample.
For H&E, paraffin-embedded sections were stained according to 
standard protocols. The regeneration area was measured by observing 
the H&E staining. The percentage of the sectional area occupied by 
ASphCs-derived differentiated cells was determined by computer-
assisted analysis (Image ProPlus software). From each section, 8 
consecutive fields were captured at 200 magnification and analyzed. 
Analysis was performed blinded by two independent observers on 3 
samples per group derived from 3 independent ASphC cultures.
In order to detect calcium deposits in the area subjected to the 
laminectomy, the von Kossa method for calcium kit (Polysciences, 
Eppelheim, Germany) was adopted and performed according to 
manufacturer’s directions. Hence, sections were placed in 3% Silver 
Nitrate Solution and exposed to UV light for 40 minutes. Then, cells 
were placed in 5% sodium thiosulfate for 2 minutes and counterstained 
with nuclear fast red for 5 minutes.
For DNA mutation analysis, DNA from paraffin-embedded 
sections was purified using QIAmp® DNA FFPE Tissue Kit (Qiagen). 
DNA samples were subjected to TruSeq Amplicon-Cancer Panel (FC-
130-1008, Illumina) and analyzed by MiSeq Reporter (MSR) software.
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Statistical Analysis
Data are explicited as mean ± standard deviation (SD). Statistical 
significance was calculated by applying Student’s t-test. Significance 
levels were indicated as p values.
* indicates P<0.05, **indicate P<0.01 and ***indicate P<0.001.
Results
Adipose spheroids comprise stem-like cells
It was postulated that adipose tissue can be regarded as a source of 
quiescent mesenchymal stem-like cells, which give rise to a population 
of heterogeneous cells that exhibit diverse degrees of differentiation. 
In order to investigate if the adipose tissue is characterized by the 
presence of a small subset of cells with a stem cell phenotype, we 
initially evaluated the presence of cells positive for different surface 
molecules, which were previously identified as putative markers for 
mesenchymal stem cells in freshly purified adipose tissue cells and 
primary adherent cells after 10 days of culture in presence of FBS. 
The surface marker levels of CD29, CD44, CD73, CD9 and CD90 
were uniformly expressed among freshly purified cells (Freshly), 
primary cells (Primary), anchorage-dependent adipose-derived stem 
cells (ADSCs) and adipose floating spheroid cells (ASphCs), with the 
exception of CD271 (Figure 1A and B).
Expression levels of CD271 were barely present on freshly 
purified cells (Freshly) and absent on primary cultures (Primary) 
(Figure 1A and C) thus, suggesting that this putative stem cell marker 
is lost in presence of high concentration of FBS, a well-known inducer 
of differentiation [30,32]. CD45 and CD19 markers were used to 
exclude the hematopoietic cells (Figure 1A). Although both ADSC 
and ASphC cultures showed high levels of CD271 expression, only 
CD271+ ASphC fraction (Figure 1D) was endowed with a potent 
sphere forming capacity, which was indefinitely maintained during 
serial in vitro passages (Figure 1E). Contrarily, CD271- ASphC and 
the CD271+ ADSC compartments failed to generate floating spheres 
when cultured in absence of serum and in presence of bFGF and EGF 
(data not shown and Supplementary Figure 1A and 1B). Moreover, 
CD271+ ADSCs in non-adherent condition gradually died up to 10 
days as compared with ASphCs which showed a significant growth 
(Supplementary 1C). Intriguingly, ASphCs, enriched in CD271+ cells, 
showed a greater multilineage differentiation potential, being able to 
originate mature adipogenic, chondrogenic and osteogenic lineages 
when cultured with specific differentiation medium (Figure 1E).
ASphCs retain differentiation capacity
ASphCs propagation, regardless of the site of origin, led to 
the observation that these cells can grow either as larger adipose 
spheroids composed by about 100 cells, as medium spheroids, or as 
small spheroids composed by almost 30 cells (Figure 2A).
To determine whether ASphCs represent undifferentiated cells 
that have retained their capacity to differentiate toward adipogenic 
(SDA), chondrogenic (SDC) and osteogenic (SDO) lineages, 
spheroids were cultured in the presence of FBS or seeded under 
adherent conditions in presence of a specific differentiation medium 
for up to 28 days. Although small spheroids purified from abdomen, 
hips and subcutaneous breast tissue showed higher differentiation 
potential than the medium and large ones, those that were breast-
derived, retained the highest differentiation capacity (Figure 2B). 
Of note, the best efficiency, in terms of absolute number of spheres 
obtained from various samples is represented by subcutaneous breast 
tissue-derived cultures (Table 1).
Although both ADSCs and ASphCs express high levels of CD271, 
only the ASphC cultures exposed to the specific differentiation 
medium, generated a progeny of propagating differentiated 
adipocytes, chondrocytes and osteoblasts up to 28 days (Figure 2C). 
ALP, OPN and von Kossa staining showed that ASphCs possess a 
strong potential to differentiate toward osteogenic lineages. Moreover, 
ASphCs grown in chondrogenic media were positive for alcian blue. 
Meanwhile, those grown in adipogenic media resulted positively 
stained for adipored. This suggests that these cells also display a 
high differentiation potential. Therefore, the ASphCs show higher 
differentiation potential compared to ADSCs grown in the same 
differentiation conditions (Figure 2D).
Among the different putative mesenchymal stem cell markers 
analysed by FACS, we found that expression levels of CD29, CD9 
and CD90 are maintained at high levels by both ASphC- and ADSC-
derived differentiated progenies (Figure 3A). In contrast, CD44 
and CD73 expression showed a distinct expression profile in the 
differentiated ASphC and ADSC subset. While CD44 expression was 
significantly reduced in differentiated cells derived from ADSC as 
compared with ADSC (Figure 3A, upper panels and 3B), in ASphCs-
derived differentiated progeny it remained highly expressed (Figure 
3A, lower panels and 3B). Of note, CD271 was significantly reduced 
in both ADSC-derived adipocytes (ADA), chondrocytes (ADC) and 
osteoblasts (ADO) and SDA, SDC, SDO (Figure 3A and 3C).
ASphCs are quiescent and show mesenchymal traits
In order to determine whether ASphCs display stem cell 
peculiarities in a quiescent state, we explored the cell cycle in our 
spheroids and ADSCs and compared them with differentiated 
progeny. ASphCs are characterized by very low clonogenic activity 
and show a large G0/G1 phase, comparable to the one present in 
ADSCs. While the G2/M and S phases in ADSC-derived adipocytes, 
chondrocytes and osteoblasts resulted unchanged with respect to the 
untreated cells, ASphC-derived cell lineages show a reduced G0/G1 phase 
and increased G2/M phase. This indicates that these latter cells retain a 
high potential to differentiate and propagate (Figure 4A). Moreover, 
ASphC-derived differentiated cells showed a greater proliferation rate 
than ADSC-derived cells. In ASphC progeny, PKH26 loss was likely due 
to the asymmetric division induced by the non-specific differentiation 
induction of FBS (Figure 4B, upper panel). In contrast, ADSCs displayed 
unaltered proliferative behavior (Figure 4B, lower panel). This confirms 
their limited capacity to be serially passed in vitro.
Then, we sought to analyze the potential changes of mesenchymal 
gene expression profile in ASphCs and ADSCs, together with their 
relative differentiated counterparts (adipogenic, chondrogenic and 
osteogenic compartments). It was revealed that ASphCs possess a more 
pronounced mesenchymal stem cell trait which is lost upon 28 days 
of differentiation in specific differentiation media, as compared with 
ADSC compartment (Figure 4C). Of note, ASphCs showed higher 
expression levels of mesenchymal stem cell markers, such as SOX2 (>5 
fold regulation) and POU5F1 (>2 fold regulation), when compared to 
ADSCs (Figure 4D, upper-left panel). The mRNA expression levels of 
PPARy (>3 fold regulation), SOX9 (>6 fold regulation), and RUNX2 
(>13 fold regulation), which are associated to specific differentiation 
in adipocytes, chondrocytes and osteoblasts respectively, resulted 
up-regulated in the differentiated ASphC progenies, compared with 
the ADSC compartment. Interestingly, when ADSCs are exposed to 
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Figure 1: CD271+ cells retain sphere forming capacity.(A) Representative flow cytometry profiles of CD29, CD44, CD73, CD271, CD9, CD90, CD45 and CD19 
on freshly purified (Freshly, green histograms), primary adipose cells (Primary, light blue histograms), adipose-derived stem cells (ADSC, purple histograms) 
and adipose spheroid cells (ASphC, pink histograms). The grey histograms represent the isotype-matched controls. (B) Fresh adipose tissue sample and its 
H&E staining on paraffin embedded sections (right panels). Phase contrast analysis of ADSC and ASphC cultures (lower panels). (C) Percentage of CD271 
positivity in Freshly, Primary, ADSCs and ASphCs performed by flow cytometry. Data are mean ± S.D. of 5 independent experiments. (D) CD271 profiles 
performed on freshly, depleted and purified adipose cells performed by flow cytometry cell sorting. Data are representative of 5 independent experiments using 
cells from different healthy donors. (E) Sphere forming and ASphC-derived adipocytes, chondrocytes and osteoblasts of CD271+ enriched ASphCs.
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specific differentiated media they show a distinctive gene expression 
pattern, including the up-regulation of BMP4 (>9 fold regulation), 
BMP7 (>9 fold regulation) (ADA), and ABCB1 (>5 fold regulation) 
(ADC) (Figure 4D).
These data suggest that ASphCs and ADSCs could reside 
at different levels within the mesenchymal stem hierarchy. This 
consideration is supported by our results in which, we compared the 
three differentiated progenies ASphCs- and ADSCs-derived, showing 
that the PPARy, SOX9, and RUNX2 are mostly up-regulated in the 
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Figure 2: ASphCs display multi-lineage differentiation ability.(A) Representative phase contrast analysis (upper panels) and fluorescence analysis of Toto3 (blue 
color, lower panels) in large, medium and small adipose tissue-derived spheroids. Data are representative of 15 ASphC cultures. (B) Percentage of differentiation 
potential of large, medium and small spheroids purified from abdomen, hips and subcutaneous breast adipose tissues. Data are mean ± S.D. of 7 independent 
experiments. (C) Percentage of ADSC (orange bars) - and ASphC (green bars)- derived adipocytes, chondrocytes and osteoblasts at the indicated time points. 
Data are mean ± S.D. of 7 independent experiments. (D) Microscopy analysis of adipored, alcian blue, alkaline phosphatase (ALP), osteopontin (OPN) (red 
color) and von Kossa (brown color) in ADSC-derived adipocytes (ADA), chondrocytes (ADC) and osteoblasts (ADO) and ASphC-derived adipocytes (SDA), 
chondrocytes (SDC) and osteoblasts (SDO).
Number of 
samples Liposuction Biopsy Gender (M/F)
Spheroids/gr of 
adipose tissue
31 Abdomen 9/20 16.7 (± 2,121)
5 Hips 6/10 11.7 (± 1,931)
2 Gluteus 0/2 10.4 (± 0,282)
3 Breast 0/3 20.8 (± 0,2)
3 Breast 3/0 5.5 (± 1,95)
Table 1: Case descriptions and sphere forming.
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p107, a marker that identifies the stem cell population of white 
adipose tissue and therefore, a master regulator of adipocytes 
differentiation, was significantly higher in ASphCs than in ADSCs. 
In ADSCs, both p107 mRNA and protein expression levels were 
comparable with those found in ASphC-derived differentiated cells. 
These data suggest that ADSCs are already programmed toward a 
terminal differentiation (Figure 4E and 4F).
ASphCs own regenerative ability
In order to evaluate ASphCs’ ability to promote bone regeneration, 
we used an in vivo murine model, which harbours a laminectomy 
at the T8 vertebral level. We sought to investigate whether ASphCs 
were able to grow and differentiate in Integra® scaffolds up to 28 days 
in presence of osteogenic medium. Interestingly, ASphC-derived 
differentiated cells highly expressed OPN (Figure 5A) showing a 
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Figure 4: ASphCs express stem cell-related genes.(A) Cell cycle analysis performed in ADSCs and ASphCs and in their differentiated progenies ADA, ADC, 
ADO and SDA, SDC, SDO after 28 days exposure to specific differentiation media. Data are expressed as mean ± SD of 4 independent experiments. (B) 
Representative PKH26 flow cytometry analysis of ADSCs and ASphCs cultured in presence of FBS at day 0 and day 14. (C) Clustergrams of mesenchymal-
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Scatter plot of mesenchymal-related genes as in (C). (E) Expression levels of p107 mRNA in ADSCs, ASphCs, ADA and SDA. GAPDH amplification was used 
as endogenous control. Results are shown as mean ± S.D. of 4 independent experiments. (F) Western blot analysis of p107 as in (E).
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Figure 5: ASphCs repair bone tissue injury.(A) Phase contrast, H&E staining and OPN immunohistochemistry analysis in ASphCs seeded on Integra® and 
cultured in vitro for 28 days. (B) Macroscopic overview of mice subjected to laminectomy at day 60 (SHAM, untreated mice; Scaffold, mice treated with only 
Integra®; ADSC and ASphC, mice treated with Integra® plus seeded cells) (upper panels). H&E, OPN (red color) and von Kossa (brown) staining on paraffin 
embedded sections in SHAM, Scaffold, ADSCs and ASphCs. Red dotted circles emphasize injured/regenerated area. Yellow boxes indicates the magnification-
matched area. Scale bars represent 150μm in 10x; 50μm in 40x. (C) Percentage of the regenerative area in the laminectomy site of mice treated as in (B). Data 
are expressed as mean ± SD of 3 independent experiments. (D) Percentage of OPN positivity as in (C). Data are expressed as mean ± SD of 3 independent 
experiments.
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great in vitro differentiation potential on Integra®. To assess the 
specific osteogenic differentiation potential of ASphC and ADSC, we 
seeded cells on Integra®, cultured for 4 days and then implanted in 
the laminectomy site (Figure 5B). Following 60 days from surgery, 
the regenerative capacity, achieved by both ASphC and ADSC, 
was evaluated by histochemistry and immunohistochemistry. 
Hematoxylin/Eosin (H&E) staining demonstrated that the tissue 
repairing capacity promoted by ASphCs, was significantly greater 
than that shown in the xenotransplantation of ADSCs (Figure 5B 
middle panels and 5C). Likewise, immunohistochemistry analysis 
for osteopontin, highlighted the significant osteogenic differentiation 
determined by the injection of ASphCs as compared with the 
regeneration potential of ADSCs (Figure 5B and 5D). The osteogenic 
nature of the new generated tissue, performed by von Kossa staining, 
confirmed that ASphCs possess a pronounced bone regeneration 
capacity, which could be peculiar characteristics of adipose stem cells 
(Figure 5B lower panels). In order to exclude any possible aberrant 
cell proliferation, paraffin-embedded over spinal sections derived 
from mice implanted with ASphCs or ADSCs seeded on Integra® 
were subjected to a mutational panel analysis for vertebral tumours 
including osteosarcoma, chondrosarcoma and liposarcoma. The most 
related gene mutations involved in the initial event of transformation 
such as TP53, BRAF, NRAS, KRAS, HRAS, PI3K resulted wild-type. 
Discussion
Here we provide evidence that spheroids derived from human 
adipose tissue are enriched with mesenchymal stem cells, which are 
an efficient source of cells, endowed with the capability of multilineage 
differentiation and repairing bone injury. Diverse approaches and 
several putative stem cell markers have been exploited to identify 
and purify the mesenchymal stem cells from adipose tissue. It was 
determined that CD9, CD29, CD44, CD90, CD105 or CD271, are cell 
surface molecules that are highly expressed in multipotent stem cell 
populations present within the adipose tissue [33,34]. It has already 
been reported that stem cells derived from adipose tissue can grow 
as floating spheres, maintaining the capacity to differentiate in vitro 
toward adipocytes, chondrocytes and osteoblasts [25,35,36]. It is likely 
that CD271 identifies both stem and progenitor cell subsets. Being that 
ADSC are cultured since the first passages in 2% FBS supplemented 
medium (which is known to drive stem cells toward differentiation), 
we can speculate that CD271 expressing ADSCs are non-clonogenic 
progenitors, which are poorly able to form floating spheroids and to 
sustain in vitro serial passages. Conversely, CD271 expressing ASphCs 
are mesenchymal stem-like subset endowed with a clonogenic activity 
that retains the multilineage differentiation capacity.
In mammals, white adipose tissue corresponds to the stem cell 
compartment and is mainly distributed among several visceral organs, 
central nervous system, subcutis and breast tissue whereas, brown 
adipose tissue is located in the scapulae and neck regions [22,37]. 
Within the white adipose tissue, there is a presence of mesenchymal 
stem cells that are associated with potent intrinsic peculiarities and 
were found located in the subcutaneous breast tissue, suggesting that 
the subcutaneous site is likely a major reservoir. Breast adipose tissue-
derived ASphCs showed a prominent specific differentiation capacity 
toward adipocytes, chondrocytes and osteoblasts.
It was demonstrated that while the transcription factor SOX9 is 
required for chondrogenic differentiation, RUNX2, which activates 
osteocalcin, is essential in osteogenesis [38,39]. Several in vivo 
studies have shown that white adipose tissue development is strictly 
dependent on PPARy activity. It was ascertained that PPARy governs, 
through the regulation of PPARy ligands’ endogenous production, 
the differentiation of mesenchymal stem cells toward the adipogenic 
lineage [40]. In line with previous reported data that highlight intrinsic 
stem cell properties, ASphCs are quiescent. Once they are forced to 
differentiate, they up-regulate the specific gene regulators that govern 
the maturation in the three different lineages. This subpopulation 
has characteristics which are inherent to mesenchymal stem cells 
that ADSCs lack on a functional level. Indeed, the ADSCs showed 
a limited capacity to be serially passed in vitro, progressively losing 
multilineage potential. Furthermore, their lineage acquisition seems 
to be governed by different pathways. So it is likely that ASphCs and 
ADSCs may reside at different levels of the stemness hierarchy.
The majority of mesenchymal stem cells often die quickly 
following an in vivo implantation [41]. Mesenchymal stem cells 
have been widely used in experimental models that are related to 
the treatment of bone diseases. To increase survival and ensure the 
differentiation in osteocytes, mesenchymal stem cells were previously 
genetically engineered and thus over-expressed AKT1, BMP2 and 
VEGF [27]. They were then transplanted into the fracture site. In this 
model, mesenchymal stem cells were not integrated into the newly 
generated bone, but they played a supportive role during the early 
stages of tissue formation. To circumvent these issues, an artificial 
scaffold has been used to prolong the mesenchymal stem cells’ viability 
as well as enhancing their differentiation capacity. In our model, ASphCs 
cultured on Integra® and implanted into the laminectomy site, were able 
to directly participate in bone tissue regeneration. Our study supports 
that a stem cell population within adipose tissue that expresses CD271, 
possesses an in vitro multipotency and harbours the capacity to repair 
bone injury that could be exploited in regenerative medicine.
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The adipose tissue may be considered as a real endocrine organ. it acts as a reservoir 
of energy of the organism, storing energy as triglycerides in times of satiety, and 
mobilize energy in the form of fatty acids in case of need. Fatty acids and their 
metabolic products could be toxic, therefore are homeostatic mechanisms to manage 
the build up of lipids and their mobilization order to avoid accumulation of 
potentially toxic in peripheral organs [1].  The ability of the adipose organ to buffer 
variations in energy supply and demand is achieved by integrated endocrine and 
metabolic responses, as well as through dynamic changes in cellular composition [2]. 
The adipose tissue buffering capacity could be overcome during chronic 
overnutrition, resulting in overflowing of lipids from adipose tissue, causing a 
pathological accumulation in other key metabolic organs. Adipose tissue can be 
discerned into three main categories: the visceral and subcutaneous anabolic white 
adipose tissue (WAT) that stores excess energy, the catabolic brown adipose tissue 
(BAT) which is responsible of dissipation of energy through heat production, and the  
“Brown and White” (brite or beige) adipose tissue. White adipose tissue (WAT) can 
expand its energy-buffering capacity by fat cell hypertrophy and/or by hyperplasia 
from committed progenitors. In contrast to WAT, brown adipose tissue (BAT) is a 
highly oxidative tissue containing multilocular fat cells with abundant mitochondria 
that oxidize fatty acids and generate heat via uncoupling protein 1 (UCP1). WAT has 
been historically defined by anatomical location and the presence of parenchymal 
cells containing a single large lipid droplet. However, WAT can be remodeled under 
various physiological and pharmacological conditions to a more oxidative phenotype 
resembling BAT. Work in experimental models has demonstrated the remarkable 
plasticity of the adipose organ [3], and it is clear that beneficial effects can be 
achieved by promoting either anabolic or catabolic phenotypes. Whether the 
adipocyte phenotypes modulation should be designed as a therapeutical approach it 
becomes essential to better understanding of adipocyte cellular types and the relative 
extrinsic signals which contribute to its development and plasticity.  
Adipose tissue composition. Adipose tissue is characterized by a marked cellular 
heterogeneity: among its cellular components, we can find adipocytes, preadipocytes, 
fibroblasts, endothelial cells and multipotent stem cells able to differentiate into 
several cell types. Overall, fat tissue consists of approximately one-third of mature 
adipocytes. The remaining two-thirds are a combination of small mesenchymal stem 
cells (MSCs), T regulatory cells, endothelial precursor cells, macrophages and 
preadipocytes in various stages of development. Preadipocytes have the ability to 
proliferate and differentiate into mature adipocytes, conferring adipose tissue a 
constant functional plasticity,which determines its ability to develop.[46] 
Adipogenesis is a finaly regulate process that has been studied for the last 30 years,. 
It could be divided into different phases, characterized by different cellular 
composition and differentiation state. [4]. Adipose tissue appears first in the 
connective tissue that contain extracellular matrix and  mesenchymal cells [5]. These 
vascular pre-structures seem to provide a framework for further recruitment of 
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progenitors and subsequent adipogenesis. In the process of adipose tissue maturation, 
the mesenchymal cells aggregate to form "lobules" possessing a reticulated structure. 
[5] In this process the most important steps are the vascularization and expansion of 
mesenchymal cells [7-9]. Finally, terminal differentiation and enlargement of 
individual adipocytes occur, which are the major modes of postnatal adipose tissue  
growth [10-11]. Application of the stem cell concept to adipose tissue biology 
launched an explosion of research into the molecular characteristics and 
differentiation potential of progenitor cells that reside in these tissue. However, the 
fact that adipose tissue depots appear at different times and possess distinct molecular 
characteristics suggests that there may be regional heterogeneity among Adipose 
Tissue depots, and in particularly in the subcutaneous and visceral ones. (Fig. 1) 
 
Figure 1.  Representative image of the mesenchymal commitment toward mature adipocyte. 
Potential adipocyte progenitor niches. Stem cells reside in specialized anatomical 
locations, known as stem cell niches, where adjacent cells or external signals from the 
microenvironment maintain their quiescence or recruitment [12-13]. The stem cell 
niche may be compartmentalized into distinct domains that enhance dormancy, or 
provide cues for proliferation and differentiation [13,15]. In particulary, 
preadipocytes have been localized to a perivascular niche during development [16,17-
18]. It is important to note that the vast majority of adipose tissue cells are not 
adipose mature cells [19-20], indeed they are a dynamic mixture of cellular and non-
cellular elements, including progenitors, resident/recruited immune cells, fibroblasts, 
blood vessels, lymphatic vessels, peripheral nerves, and extracellular matrix (ECM).  
Adipose tissue macrophages. The adipose tissue macrophages are a critical cell type 
for the metabolic and endocrine adipose tissue functions [83,84]. The macrophages, 
based on their functional phenotypes, have been classified into two subpopulations: 
the M1 macrophages that are associated with the defense responses and pro-
inflammatory immune, and the M2 macrophages that are involved in tissue repair 
[21-22]. Macrophages depletion impairs adipogenesis and macrophage-conditioned 
medium could inhibit preadipocyte apoptosis and promote survival [23-24]. In 
addition, macrophages are a major source of angiogenic factors and can indirectly 
mediate Adipose Tissue expansion [25]. However, every specific effects of 
macrophages have not been investigated. Pro-inflammatory M1 macrophages 
accumulate in adipose tissue during obesity and thereby could promote insulin 
resistance. [26-27] 
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Vasculature. Experimental data suggest that angiogenesis and adipogenesis are 
tightly coupled during development. In vitro studies suggest that signals derived from 
surrounding vascular units directly influence preadipocyte proliferation and 
differentiation. The vascular-derived signals remain poorly characterized [9,28-29]. 
Several studies have shown that overexpression of VEGFA improves metabolic 
profiles and prevents adipose tissue dysfunction during the early phase of obesity . In 
contrast, reducing vascularization during obesity may improve metabolic outcomes 
by inducing apoptosis in dysfunctional adipocytes [30]. 
The adipose extracellular matrix (ECM). It is an adipose stromal component that 
provides structural support and biochemical signals to maintain tissue function. 
Importantly, physical and biochemical elements of ECM can affect MSC lineage 
specification, proliferation, and differentiation.on the other hand the adipocytes 
progenitors play an important role in ECM remodeling. [31-33]. I.e, their 
differentiation rapidly upregulate expression of collagen IV and various laminin 
complexes. Contrary, fibronectin expression decreases during adipocyte 
differentiation [34-36]. Together, these findings suggest that ECM configuration 
undergoes a transition from a fibrillar to a laminar structure to accommodate 
adipocyte growth and fat storage [33]. ECM degrading enzymes, includes fibrinolytic 
enzymes and numerous matrix metalloproteinases (MMP), play a crucial role in 
modifying ECM structure creating a permissive environment for adipose tissue 
growth/remodeling. [37]. Dysregulation of ECM synthesis could lead to fibrosis and 
adipose tissue disruption. Fibrosis is a common pathophysiological response to 
chronic injury in which excess accumulation of fibrotic ECM distorts tissue 
architecture and impairs the function of parenchymal cells [38]. During obesity, 
metabolically-challenged adipose tissue increases fibrous collagen production and 
upregulates related genes. Adipose tissue macrophages, which are recruited in obese 
states, contribute to fibrosis by stimulating fibroblast ECM synthesis. 
Pathological role of adipose tissue. Substantial evidence suggests that adverse 
consequences of obesity have their origins in the pathological remodeling of adipose 
tissue [39]. Obesity is a major disease in recent decades, it is associated with 
increased incidence of many diseases, including cancer. It is known that obesity is 
associated with a generalized inflammation, with an elevated expression of 
inflammatory cytokines and recruitment of macrophages, an endothelial dysfunction 
and a wide adipocyte death [40-43]. A chronic overnutrition, infact, increases the 
occurrence of hypertrophic fat cells, which become distressed and undergo 
necrosis/apoptosis reaching a critical size. Adipocyte cell death recruits macrophages 
and triggers a local inflammatory response [44-45]. Furthermore there are secreted 
molecules called adipocytokines, that exert a significant effect on every adjacent cells 
included the immune system. For  these reasons adipose tissue could be considered 
not only a simple energy storage tissue system but it could be considered an 
important endocrine and immune organ, whose hormones, however, not yet fully 
characterized. Moreover recent studies on inflammatory cells infiltrating the adipose 
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tissue highlight that these cells generate a specific environment that perpetuates the 
inflammation within tissues and activate adipocytes to produce others inflammatory 
mediators and adipocytokines, creating a virous circle between inflammation and 
obesity [47]. A depth study of each molecule released from adipose tissue there are 
necessary. In particular in our study the key issue becomes identifying the main 
cytokines responsible of an inflammatory and pro proliferative microenvironment. 
The tumor and tissue microenvironment are indeed closely related. It is well 
established that the microenvironment plays a critical role in cancer development and 
metastasis formation. It has been demonstrated that obesity promotes significant 
changes in the biological properties of Adipose Stem Cells (ASC). [48]. Although 
current knowledge of the biological impacts of MSCs on tumor development is 
greatly improved, the underlying effects of MSCs from different origin remain 
controversial. Fact, adipose tissue adjacent to tumor is thought affect tumor 
progression, which may be the alternative mechanism of cancer incidence associated 
with obesity, since ASCs reveal tropism to inflammatory sites and tumor lesions, and 
could contribute to the tumor microenvironment, promote a higher cancer progression 
and also an invasion and migration of cancer cells. [49-50]. Accumulating evidence, 
indicates that ASCs promote tumor growth and metastasis of various cancers [51-54], 
whereas conflicting reports reveal the anti-tumorigenic potentials of ASCs such as 
anti-proliferation and pro-apoptosis [55-57]. MSCs have been proposed as an 
attractive candidate in the regenerative medicine for their ability to home into tumor 
sites and to secrete anti-tumor agents [58], but the recent findings suggest that the 
MSC-secreted soluble factors in a tumor microenvironment may contribute to a tumor 
progression [51,57]. (Fig. 2) 
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Figure  2. White adipose tissue presence in tumours.  
The tumor and adipose tissue are closely related and constantly interacted. (British Journal of 
Cancer (2015) 112, 419–423. doi:10.1038/bjc.2014.657) 
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Breast cancer 
Breasts are equal and symmetrical glandular organs placed in the district 
subcutaneous of the front and upper female chest. The breast is a composed tubule-
alveolar gland consists of 15-20 lobes plunged in the adipose tissue and sedimented 
of connective laminae. Each lobe consists of several lobules containing alveoli 
secreting glandular units, each of these posses its own excretory galattoforo duct 
which is divided into lobular ducts that continued in lobular alveolar ducts flowing 
into the alveoli terminals and finally converging into a single large duct in the nipple. 
Breast carcinoma represents the most common neoplasia in women with a ratio of 
25%, responsible for over 400,000 deaths every year. The incidence of the disease 
varies widely in different geographical areas with a higher prevalence in 
industrialized countries. In Italy about 37,000 cases are diagnosed. The age in which 
there is the highest breast cancer incidence is between 45 and 50 years. The 
individual risk is indeed influenced by many different factors such as family history, 
age, lifestyle and environment. (Figure 1) 
 
 
Figure 1.  Breast anatomy and breast cancer incidency 
The detected mutations of some tumor suppressor genes such as BRCA-1 (BRCA1) 
and Type 2 (BRCA2) in chromosome 17 or p53 mutations increase the breast cancer 
risk. The most widely accepted opinion, however, is that the breast cancer onset  
hormonal factors play the higher significant causative role[1]. 
The breast invasive carcinomas classification for many decades was done on the 
histologic type and grade basis  
• Epithelial: derived from glandular epithelium, which lines the inside of the 
ducts and lobules. 
 
• Fibroepiteliali: it is made of epithelial and mesenchymal or stromal 
components 
 
• Mesenchymal: cancer  type observed in so-called soft tissue, such as skin and 
subcutaneous tissue. 
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• Miscellaneous: rare cancers, which are not grouped in the previous classes. 
 
The most common breast cancer type  is the epithelial lesion, and the most frequent 
histotypes are ductal carcinoma and lobular that. 
Ductal carcinoma develops in the galactophorous ducts while the lobular develops in 
the glands galattofore. The two histotypes may be "in situ", that is non-invasive, or 
"infiltrating". In the first case it is a tumor intraepithelial, that is, the surface in which 
there is no migration in the underlying tissues and not to be exceeded the basement 
membrane. 
This neoplasia could be characterized either on the basis of different stages of the 
disease that in relation to the originating site and thus will distinguish a ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). 
When cancer cells  beyond the surface epithelium and spread within the underlying 
tissues through the lymph vessels and blood, invading More distant organs giving rise 
new centers of the disease, in this case we talk about tumor infiltrating or invasive 
and the most common is ductal histology (DIC = Invasive ductal carcinoma), which 
represents about 75% of tumors infiltrating lobular while about 5%. Other histologies 
infiltrating less frequent are the medullary carcinoma (15%), colloid or mucinous 
(2%), the tubular (1-2%), to which are added several other rare forms. [2]: 
 
 
 
Figure 2 Breast Cancer Staging on the basis of TNM classification. 
 
Together with the histological characterization, there is a sub molecular classification 
on the basis of gene expression and identified five subtypes of breast cancer: luminal 
A, luminal B, HER2-enriched, basal-like and claudin-low. 
27
 Luminal A: 
It is characterized by the expression (94%) of the receptors for the steroid hormone 
estrogen (ER). These tumors are typically positive for the progesterone receptor (PR), 
although there is a subtype of ER + / PR-, furthermore express other markers luminal 
epithelium-specific protein such as intermediate filament cytokeratin (CK18) and 
MUC1, and can be positive (9%) or negative (92%) for the receptor of the human 
epidermal growth factor 2 (HER2). According to this pattern genetic, luminal tumors 
are made up most part to differentiated cells sensitive to hormonal treatments, and 
therefore have a much more favorable prognosis than those with triple negative 
phenotype (NPT), which lack ER, PR and HER2 (4-5%), to which correspond 
phenotype local recurrence and dissemination to distant sites.[3-4] 
The Basal-like (BL): 
it is characterized by low or absent gene expression markers luminal: ER (91%), PR- 
/ low, Hermann / low, in fact, this subtype is the high percentage (39-54%) of the 
NPT. Such class of breast tumors express low levels of other markers luminal as 
GATA3 and CK18 and 19 against and are highly expressed basal cytokeratins CK5, 
CK14, and CK17. As part of the markers of stem / progenitor the BL show high gene 
expression of CD44 molecules, CD49f and ALDH-1 and rather low expression of 
epithelial differentiation markers including CD24, EpCAM and MUC1. However, 
recent experimental evidence state that the BL levels of CD24 / EpCAM and ALDH-
1 are not significantly lower and higher, respectively . Therefore within cancers basal 
can be found CD44 + CD24low CD49f + and + / high EpCAM + cell populations. 
Thompson and Snow have also shown that in these subtypes of tumors is elevated 
gene expression of markers of transaction epithelial mesenchymal (EMT) whose 
predominant function is to suppress the E-Cadherin (glycoprotein of calcium-
dependent cell-cell adhesion) in directly through Snail1, Snail2, Zeb1, Zeb2, TCF3 
and indirectly through TWIST1, Twist2, Id1, TCF4, FOX2 and NFkB . The 
molecular profile of the BL is therefore consistent with an enrichment of epithelial 
cells and undifferentiated tumor with mesenchymal characteristics, ie a high density 
of ICT / CST whose antigenic phenotype coincides with the expression pattern of the 
gene of the BL. The high percentage of SC cells / progenitors in BL would be the 
cause of the resistance to current hormone therapies and chemotherapy and is 
therefore associated with a poorer prognosis than luminal subtypes.[3,5-6] 
The Claudin-low (CL)  
It was first identified in 2007. The name comes from the low levels of expression of 
genes involved in the junctions occluding such as Claudina 3, 4, 7 and occludin. The 
pattern and the molecular phenotype of this cancer subtype is very similar to the 
subtype BL fact also has a high percentage (25-39%) of the NPT, negativity for 
cytokeratins CK18 luminal and 19 and high expression of basal cytokeratins CK5, 
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CK14, and CK17. CL also tumors have high density cell populations with phenotype 
CD44 + / CD24- high / low and CD49f + / high EpCAM- and high levels of ALDH-1 
unlike the BL. Studies conducted by Thompson and Snow show that even in these 
tumor subtypes there is an expression of the marker gene EMT even higher than the 
BL; However, the same studies show that the distinct characteristics present in the 
mesenchymal cells of the CL as well as in BL, are only associated with epithelial 
tumor cells and not due to contamination from adjacent stroma [6]. E 'was also noted 
that in CL there is a high expression of genes involved in the immune system's 
response (CD79, CD14, Vav1), this data suggests a potential recruitment of different 
types of leukocytes in this type of tumors. The CL, in agreement with the high 
expression of mesenchymal markers / normal stem cells, presents a higher percentage 
of ICT normal stem cells / progenitors compared to BL which makes them slightly 
sensitive to chemotherapy (neo adjuvant anthracycline / taxane) but which total can 
not be eradicated and therefore are linked to a very poor prognosis. 
Luminal B 
this class of breast cancer has a molecular profile and phenotypic HR + (ER + PR +) / 
HER2 +. The Ki-67 protein has been studied as a potential marker of 
immunohistochemistry (IHC) that could distinguish subtypes luminal B tumors than 
A. High expression of Ki-67 (therefore highly proliferative) were associated with 
luminal B unlike luminal Type A [7]. Kabose and Horwitz (2010) have shown that 
this type of breast cancer presents a certain heterogeneity. Studies show that the 
luminal B subtype is not only relatively (compared to the BL and HER2-enriched) 
chemo-insensitive (anthracycline / taxane) but also resistant to hormone therapy. The 
biology of the luminal B could be explained by the resistance mechanisms of 
hormone therapy including activating ligand-independent ER by the family of HER 
receptors, which could cause resistance to endocrine therapies in cancers basal ER + / 
HER2 + but also in ER + / HER2 thanks to an activation in an alternative signal of 
HER. Two clinical trials have tested this hypothesis by showing that a combination 
therapy, endocrine and anti-HER2 (trastuzumab), increased survival in breast cancer 
patients with HR + / HER2 + metastatic. However, many patients do not benefit from 
HER2 + therapy with trastuzumab [8-10]. 
The HER2-enriched 
It is characterized by overexpression of the HER2 receptor. It also shows mainly 
negativity for ER (69%); The tumors belonging to this subtype exhibit the loss of 
expression of gene cluster and low basal expression of gene cluster luminal if 
compared to that of luminal A and B [3]. Cell populations belonging to this subtype 
have high transcriptional levels of CD24 [6]. Recent studies show a high chemo-
sensitivity (anthracycline / taxane) subtype HER2-enriched and Basal-like (widely 
ER-negative), but despite the high response to chemotherapy, the occurrence of 
relapses due to the "minimal residual disease "greatly improves the survival free of 
disease progression in patients with ER + tumors (primarily luminal). The molecular 
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characterization and phenotypic then shows how the intrinsic subtypes of breast 
cancer could be made up of cells resembling those of normal tissue at different stages 
of differentiation as evidenced by recent studies Lim et al. (2009). On the origin of 
the development of the intrinsic subtypes have been several hypotheses; one of these, 
in line with the theory of the CST, said the SC could be the origin of any intrinsic 
subtype. In this context, the transformed cells SC are capable of experiencing division 
symmetric and asymmetric, the latter capable of generating differentiated cells that 
are stopped at a specific stage differentiation dependent on the particular cancer 
subtype. There was therefore a bulk tumor composed of cells more or less 
differentiated, with a subpopulation of cells with characteristics of CST / ICT. 
According to another hypothesis the different molecular subtypes may not originate 
directly from alterations in SC but CST derived from a de-differentiation of 
differentiated cells transformed into cancer. Other authors instead argue that the 
different subtypes could arise from transformed cells that are found at different levels 
of luminal differentiation of normal breast. In this context, the SC would give rise to 
tumors CL, luminal progenitors to BL and luminal cells mature tumors luminal A and 
B; However, this hypothesis contrasts with other studies (in support of the theory of 
CST) that a smaller percentage of ICT / CST (CD44 + / CD24-) is observed in all 
tumor subtypes. Numerous experimental evidence, however, have supported that the 
origin of CL and BL are stem cells, in contrast to the more differentiated subtypes 
(Luminale A, B and HER2 enriched). In this context Prat and Perou (2011) are more 
favorable to a combination of these theories: CL and BL originerebbero from the 
processing of a normal stem cells, with limited differentiation into progenitors in the 
case of luminal tumors BL, instead luminal tumors may arise from a transformation 
of differentiated cells [3]. 
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 Figure 3. Molecular Classification of  Breast Cancer Subtypes (lower panel) and  Pyramidal 
hierarchy of breast cancer subtypes, the apex we find the most undifferentiated and poor 
prognosis subtype to most differentiated and favorable prognosis ( upper panel). 
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Stem cells 
The adult stem cell is a cell highly undifferentiated with distinct replicative capacity 
and is capable of giving rise to all cell types of the organism through a process of 
differentiation. The classic definition of a stem cell gives it two essential properties: 
the self renewal and potency [11]. The self renewal or self-renewal is the ability to 
generate daughter cells with the same characteristics of the mother cell during each 
cell replication. Stem cells in fact undergo asymmetric cell division giving rise to two 
different daughter cells, one identical to the parent cell and another, called progenitor, 
with the properties of a cell more specialized and differentiated.  
 
 
 
Figure.1: Representation of the properties of a stem cell to do a asymmetric division. 
 
The potency represents the ability of the cell to differentiate into various specialized 
cell types. Stem cells have a great plasticity and differentiation based on this are 
classified into totipotent, pluripotent, multipotent and unipotent. 
 Totipotent cells have the ability to reason a complete individual, retain the 
ability to differentiate into all cell types and fetal membranes and possess an 
unlimited proliferative capacity and multiplicative. 
 The pluripotent cells have lost the ability to give rise to a complete individual, 
have multiplicative and proliferative capacity, maintain immortality and cell it 
remains unchanged the ability to differentiate into all cell types except the 
fetal membranes. 
Stem cell
Committed
Stem cell
Progenitor
Precursor
Somatic cell
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 Multipotent cells have lost the immortal cell but retain the ability to 
differentiate.[11] 
 
Depending on their origin, the stem cells are also classified in embryonic, fetal and 
adult. 
 The embryonic stem cells are pluripotent and totipotent. The first resident in 
the zygote and embryo until the third cell division, the latter are present in the 
embryo until the first week after fertilization. Cells are able to perform an 
unlimited number of symmetrical divisions without differentiating. 
 
 The fetal stem cells are pluripotent and multipotent stem. They are present in 
the fetus during the developmental period that goes from the tenth week of 
gestation until birth and can be found in the umbilical cord, placenta and 
amniotic fluid. 
 
 The adult stem cells are multipotent and unipotent. District are cells, 
undifferentiated and deputies to tissue regeneration. They are present in the 
bone marrow and other tissues such as the neural tissue, skin, adipose tissue 
and many other tissues. They have the ability to both self-renew is to 
differentiate into various specialized cell types of the tissue / organ of 
belonging and generate intermediate cells called undifferentiated progenitors. 
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The Cancer Stem Cell Concept 
In recent years the views of the scientific community on cancer biology has 
drastically changed. In 1976 Nowell had described the stochastic model according to 
which the tumor originated from any cell of the body following the acquisition of 
multiple mutations borne by those genes that promote cell proliferation (oncogenes) 
or the genes responsible for the inhibition of cell cycle (tumor suppressor genes). 
According to this model the mutant progeny could acquire additional mutations 
generating a genetically heterogeneous tumor. So according to this model of clonal 
evolution, each cell could be the target of malignant transformation [12]. Based on 
this assumption, however, he would not find an explanation for the failure of current 
cancer therapies aimed at killing cells proliferating. 
In recent years, therefore it has been proposed a different model of carcinogenesis, 
defined '' hierarchical '', according to which a tumor would have originated from a 
small portion of cells called '' cancer stem cells '' (TSA). This different theory has 
taken shape by experimental evidence that, although the tumor originated from a 
clone, the cell population is not homogeneous as in the course of proliferation cells 
acquire new mutations. The hierarchical model therefore submits that the tumor mass 
would be composed of a large number of cells capable of proliferating in a limited 
manner and by a rare population of cells responsible for the growth and neoplastic 
progression, capable of proliferating in the long and maintain the tumor (Figure.5 ). 
The stochastic model was also refuted by experimental evidence that in the animal 
model of reference was necessary to inoculate a large number of tumor cells for the 
obtaining of a xenograft. As opposed to the model of CST it is seen that a small 
fraction cell is necessary and sufficient for the recapitulation of the tumor starting 
[13-15]. 
 
Figure. 5: Rappresentazione grafica dei differenti modelli di carcinogenesi. A) Modello 
stocastico,  le cellule tumorali sono eterogenee e la maggior parte di esse può proliferare e 
generare nuovi tumori. B) Modello gerarchico, le cellule tumorali sono eterogenee e solo la 
sottopopolazione delle CST (Cellule Staminali Tumorali) possiede la capacità di proliferare  
ampiamente e formare nuovi tumori (Weissman et al., Nature, 2001). 
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 The first demonstration of the existence of the CST was provided by Dick and 
colleagues at the end of the nineties, using as a model the acute myeloid leukemia 
(AML). Sorting by flow cytometry, it was isolated a subpopulation of CD34 + CD38- 
phenotype characterized. Although these represent only a small percentage of all 
leukemic cells, CD34 + CD38- were the only ones capable of giving rise to leukemia 
in mice immunocompromised NOD / SCID (Non-Obese Diabetic / Severe Combined 
immunodeficient) and to keep this potential following serial transplantation. Also 
obtained from the xenograft mouse model, it was the exact phenocopy parental tumor, 
confirming that the CD34 + CD38- fraction was able not only to self-renewal, but 
also to give rise to a more differentiated progeny [16]. An alternative method to flow 
cytometry sorting, for the isolation of the CST, is the sage of side population (SP), 
which refers to the high expression of membrane transporters ABC (ATP Binding 
Cassette) providing the stem cell's ability to mediate the outflow of the 
chemotherapeutic drug and some dyes such as Hoechst 33342 [17]. This method is 
now little used and supplanted by the identification of stem cell markers that is the 
subject of scientific debate. Some markers currently used to enrich the population of 
cancer stem cells are CD133 for glioblastoma, colon, pancreas, lung liver and 
prostate; and CD44, CD24 for the pancreas, ovary, head and breast [18]. For this 
reason the molecular targeting of such highly tumorigenic cells becomes fundamental 
to improve the efficacy of current anti-cancer strategies, aiming to sensitize tumours 
to conventional therapies thus definitely abrogate tumorigenesis.The main problem in 
CSC research is the identification and characterization of this cell subset, to study 
their biology and design new specific target therapy against them. In this regard the 
use of biomarkers, for CSC purification (most of the time by cell sorting, using 
membrane markers), has given a great contribute in the field. The panel of biomarkers 
used is different in different types of cancer, as shown in Table 1. 
Table 1. CSC markers 
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The specificity of each marker is often questioned by different research groups for 
several reasons, i.e. the sequential cell sorting purifying CSCs having all the CSC 
markers has never been reported in literature (it is not rare to find a CSC population 
expressing one marker and not another one) [19] and sometimes these markers are 
also good markers of normal tissue adjacent to the tumour [20]. 
CSC state is increasingly being seen as a flexible, rather than fixed, quality of tumour 
cells that can be lost and gained over time [21]
)
. These events could lead to a 
spatial/temporal intra-tumour heterogeneity (ITH) that may contribute to some of the 
difficulties in validating biomarkers for clinical use, despite the continued discovery 
of potential novel biomarkers [22]. CSCs are indeed used nowadays as a marker of 
tumour aggressiveness and drug resistance, the CSC number and phenotype is also 
used by clinicians to decide the best treatment to apply. Despite the considerable 
progress made in cancer research, the majority of patients still do not show 
advantages by the use of a particular anti-cancer therapy, this phenomenon could be 
explained by ITH [23]. The ITH was initially proposed in 70’s and justified by the 
continuous selection of tumour cells due to the applied regimen and by the CSCs 
differentiation. It was recently demonstrated that about two thirds of the mutations 
found in single biopsies of renal cell carcinoma were not expressed through all the 
sample regions of the patient’s tumour [24]. An important role in the generation and 
maintenance of ITH is certainly played by the microenvironment (the tumour, such as 
the normal tissue, possess a variable architecture, in terms of vascularisation, 
infiltration degree and connective tissue components) and the chemo- or radio-
treatment. Recent studies using sequential sequencing through different lines of 
therapy highlighted the effect of DNA damaging agents, leading to the expansion of 
resistant clones, or generating new cell populations as a result of new genomic 
alterations gained during the therapy [25-26]. According to the same model of spatial 
and temporal ITH, it was recent demonstrated that even if the metastatic lesions are 
related to primary tumours, they sometimes carry additional mutations in functionally 
important loci completely absent in the primary tumour [27-29], this discovery 
resulted fundamental since most of the therapeutic decisions are based on the primary 
tumor analysis. 
Breast cancer stem cells 
In an experimental study reported by Al-Hajj and colleagues in 2002 are identified by 
flow cytometric sorting '' cells initiators breast cancer '' based on the expression of 
surface antigens such as CD44, CD24, ESA [30-31] (Fig. 7). CD44 is the receptor 
activity iauloronico, but it can also interact with other ligands such as osteopontin, 
collagen, FGF and MMPs; CD24 is a glycoprotein that is part of the category of cell 
adhesion molecules; ESA (Epithelial Specific Antigen) is a transmembrane 
glycoprotein of 40kDa portion expressed in the basolateral surface of the epithelial 
cell. 
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Subsequently, additional markers were used for the characterization of these cells as 
CD133, a glycoprotein with five domains transmembranari and the ALDH1, the 
isoform 1 of the aldehyde dehydrogenase, an enzyme which oxidizes aldehydes 
intracellular detoxifying and converts retinol to retinoic acid. In particular a study by 
Ginestier and colleagues in 2007, it was assumed that ALDH1 was able to protect the 
cells from oxidative stress allowing a greater survival and even modulating the 
proliferation, with experiments conducted both in vitro and in vivo shows that 
epithelial cells breast, both normal and tumor cells with increased activity of the 
enzyme ALDH1, have characteristics of stem cell [32-33]. For which cells CD44 + 
CD24- and ALDH 1, possess tumorigenic capacity, being able to generate tumor in 
immunocompromised mice since the inoculation of 20 cells. In the same study it was 
also shown that cells CD44 +, CD24- and ESA + would generate cells CD44 + and 
CD24- additional, confirming the theory of asymmetric cell division, maintaining the 
characteristics of self-renewal and the generation of a population heterogeneous cell 
also not tumorigenic that constitute the so-called tumor mass. Recent work by Pitch 
and colleagues of  2010 also proposed, as a method for the isolation and purification 
of stem cell component from mammosfere cancer, FACS analysis (Fluorescence 
Activated Cell Sorter) by marking the cells with the vital fluorescent dye PKH-26 . In 
accordance with the fluorescence intensity it is then possible to select a population 
PKH-26 
+
 '' stem-like '' (high intensity of dye) and a population PKH-26 
-
 '' dividing 
cells '' (low intensity of dye ). According to this profile is therefore possible to predict 
the biological and molecular characteristics of different mammary carcinoma: poorly 
differentiated or well differentiated. 
 
  
37
 Figure. 6  Isolamento delle cellule iniziatrici il tumore al seno ( Al-Hajj et al. , PNAS,  2002). 
 
 
 
 
 
 
 
 
 
 
 
 
  
38
References  
1. Peto J  Cancer Epidemiology.Nature,411,390-395.2001 
2.  Turner,N.C. & Reis-Filho,J.S Oncogene(2006) 
3. Prat, A. And C.M. Perou, Deconstructing The Molecular Portraits Of 
Breast Cancer. Mol Oncol, 2011. 5(1): P. 5-23.]  
4. Cui, X., Et Al., Biology Of Progesterone Receptor Loss In Breast Cancer 
And Its Implications For Endocrine Therapy. J Clin Oncol, 2005. 23(30): 
P. 7721-35.;] 
5. Blick, T., Et Al., Epithelial Mesenchymal Transition Traits In Human 
Breast Cancer Cell Lines Parallel The CD44(Hi/)CD24 (Lo/-) Stem Cell 
Phenotype In Human Breast Cancer. J Mammary Gland Biol Neoplasia, 
2010. 15(2): P. 235-52  
6. Prat, A., et al., Phenotypic and molecular characterization of the claudin-
low intrinsic subtype of breast cancer. Breast Cancer Res, 2010. 12(5): p. 
R68. 
7. Cheang, M.C., Et Al., Ki67 Index, HER2 Status, And Prognosis Of 
Patients With Luminal B Breast Cancer. J Natl Cancer Inst, 2009. 
101(10): P. 736-50 
8. Agus, D.B., Et Al., Targeting Ligand-Activated Erbb2 Signaling Inhibits 
Breast And Prostate Tumor Growth. Cancer Cell, 2002. 2(2): P. 127-37. 
9.  Menendez, J.A., I. Mehmi, And R. Lupu, Trastuzumab In Combination 
With Heregulin-Activated Her-2 (Erbb-2) Triggers A Receptor-Enhanced 
Chemosensitivity Effect In The Absence Of Her-2 Overexpression. J Clin 
Oncol, 2006. 24(23): P. 3735-46 
10.  Johnston, S., Et Al., Lapatinib Combined With Letrozole Versus 
Letrozole And Placebo As First-Line Therapy For Postmenopausal 
Hormone Receptor-Positive Metastatic Breast Cancer. J Clin Oncol, 
2009. 27(33): P. 5538-46 
11. Mayhall.E.A., Paffet-Lugassy,N&Zon. Current Opinion In Cell Biology 
(2004). 
12. Nowell, P.C., The Clonal Evolution Of Tumor Cell Populations. Science, 
1976. 194(4260): P. 23-8.] 
13. Reya, T., Et Al., Stem Cells, Cancer, And Cancer Stem Cells. Nature, 
2001. 414(6859): P. 105-11 ;  
39
14. Vermeulen, L., Et Al., Cancer Stem Cells--Old Concepts, New Insights. 
Cell Death Differ, 2008. 15(6): P. 947-58 
15. Pardal, R., M.F. Clarke, And S.J. Morrison, Applying The Principles Of 
Stem-Cell Biology To Cancer. Nat Rev Cancer, 2003. 3(12): P. 895-902.] 
16. Bonnet, D. And J.E. Dick, Human Acute Myeloid Leukemia Is Organized 
As A Hierarchy That Originates From A Primitive Hematopoietic Cell. 
Nat Med, 1997. 3(7): P. 730-7. 
17. Wu, C., Et Al., Side Population Cells Isolated From Mesenchymal 
Neoplasms Have Tumor Initiating Potential. Cancer Res, 2007. 67(17): P. 
8216-22]. 
18. Boman, B.M. And M.S. Wicha, Cancer Stem Cells: A Step Toward The 
Cure. J Clin Oncol, 2008. 26(17): P. 2795-9. 
19. Floor SL, Dumont JE, Maenhaut C, Raspe E. Hallmarks of cancer: of all 
cancer cells, all the time? Trends Mol Med. 2012 Sep;18(9):509-15. 
20. Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis 
MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster 
AM, Woodward WA, Chang JC. Cancer stem cell markers are enriched in 
normal tissue adjacent to triple negative breast cancer and inversely 
correlated with DNA repair deficiency. Breast Cancer Res. 2013 Sep 
4;15(5):R77 
21. Medema JP. Cancer stem cells: the challenges ahead. Nat Cell 
Biol. 2013 Apr;15(4):338-44.  
22. Poste G. Bring on the biomarkers. Nature. 2011 Jan 13;469(7329):156-7.  
23. Marusyk, A., Almendro, V., Polyak, K. Intra-tumour heterogeneity: a 
looking glass for cancer? Nat Rev Cancer.  2012.12 (5), 323–334. 
24. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., 
Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, 
I., Phillimore, B., Begum, S., McDonald, N.Q., Butler, A., Jones, D., 
Raine, K., Latimer, C., Santos, C.R., Nohadani, M., Eklund, A.C., 
Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, 
Z., Downward, J., Futreal, P.A., Swanton, C., 2012. Intratumor 
heterogeneity and branched evolution revealed by multiregion 
sequencing. N. Engl. J. Med. 366 (10), 883–892. 
25. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van 
Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar 
SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL. Clonal 
40
competition with alternating dominance in multiple myeloma. 
Blood. 2012 Aug 2;120(5):1067-76. 
26. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari 
S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca 
R, Bergsagel PL, Craig DW,Carpten JD, Stewart AK. Whole-genome 
sequencing of multiple myeloma from diagnosis to plasma cell leukemia 
reveals genomic initiating events, evolution, and clonal tides. 
Blood. 2012 Aug 2;120(5):1060-6. 
27. Stoecklein, N.H., Klein, C.A. Genetic disparity between primary tumours, 
disseminated tumour cells, and manifest metastasis. Int. J. Cancer  2010 
126 (3), 589–598. 
28. Shah, S.P., Morin, R.D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., 
Delaney, A., Gelmon, K., Guliany, R., Senz, J., Steidl, C., Holt, R.A., 
Jones, S., Sun, M., Leung, G., Moore, R., Severson, T., Taylor, G.A., 
Teschendorff, A.E., Tse, K., Turashvili, G., Varhol, R., Warren, R.L., 
Watson, P., Zhao, Y., Caldas, C., Huntsman, D., Hirst, M., Marra, M.A., 
Aparicio, S. Mutational evolution in a lobular breast tumour profiled at 
single nucleotide resolution. Nature. 2009 461 (7265), 809–813. 
29. Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, 
M., Hruban, R.H., Eshleman, J.R., Nowak, M.A., Velculescu, V.E., 
Kinzler, K.W., Vogelstein, B., Iacobuzio-Donahue, C.A. Distant 
metastasis occurs late during the genetic evolution of pancreatic cancer. 
Nature. 2010 467 (7319), 1114–1117. 
30. Al-Hajj, M., Et Al., Prospective Identification Of Tumorigenic Breast 
Cancer Cells. Proc Natl Acad Sci U S A, 2003. 100(7): P. 3983-8 
31. Prat, A., Et Al., Phenotypic And Molecular Characterization Of The 
Claudin-Low Intrinsic Subtype Of Breast Cancer. Breast Cancer Res, 
2010. 12(5): P. R68 
32. Chute, J.P., Et Al., Inhibition Of Aldehyde Dehydrogenase And Retinoid 
Signaling Induces The Expansion Of Human Hematopoietic Stem Cells. 
Proc Natl Acad Sci U S A, 2006. 103(31): P. 11707-12. 
33. Ginestier C, Hur MH, Charafe-Jauffret E, Montville F, Dutcher J, Brown 
M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum 
D, Wicha MS, Dontu G. ALDH1 Is A Marker Of Normal And Malignant 
Human Mammary Stem Cells And A Predictor Of Poor Clinical 
Outcome.. Cell Stem Cell. 2007 Nov;1(5):555-67. 
  
41
  
 
 
 
 
 
 
 
 
 
 
 
Chapter| 4  
42
The role of adipose-microenviroment in breast cancer relapse 
 
Introduction 
Mesenchymal stem cells were studied for the first time in the early 70s by Friedestein 
and colleagues [60]. The main characteristics of MSCs were first described in bone 
marrow tissue, that represents a suitable source of mesenchymal stem cells and which 
are used routinely in clinical applications, revealing a promising alternative source for 
further development in regenerative medicine [61-63]. Over the last 15 years, 
however, the attention was focused on finding an abundant valuable alternative 
source of multi-potent stem cells MSCs can also be isolated in minimal quantities 
from other tissues[64-65]. The difficult accessibility and low volumes of tissue 
obtained ex vivo, limit the clinical use of bone marrow-derived stem cells. Their 
harvest requires a painful procedure, neither of which is free from complications and 
with a low compliance of the patients. Recent studies have shown that mesenchymal 
stem cells derived from adipose tissue can differentiate into a variety of cell lines 
(cardiomyocytes, myocytes, neurons, adipocytes, osteocytes, chondrocytes) and 
improve the neo-vascularization of ischemic tissue.[66-68] Thus the adipose tissue is 
considered an ideal source of MSCs in association with therapeutic needs and in 
particular for the repair of defects in the regenerative medicine, since their isolation is 
achieved by means of a minimal invasive surgery.[69-71] 
Surgical techniques: Mastectomy is the surgical breast resection, it is often the only 
possible therapy for the breast carcinoma, depending on the severity of the underlying 
disease, there is a single mastectomy, a radical mastectomy, a modified radical 
mastectomy or others. [74-75] Liposuction is a safe and non-invasive procedure, 
routinely performed through a 2-3 mm skin incision and well-accepted by patients 
who normally undergo this procedure. Lipofilling is surgical transfer of autologous 
fat tissue to areas of body that need to be filled. Over the last 15 years this method has 
been used just for purposes in partial reconstruction of the breast [76]. This technique 
consists in aspiring the fat from the patient, through micro cannulas, filtering and 
centrifugation process, after which the fat is reinserted in the breast. Lipofilling has 
been indicated for post mastectomy breast reconstruction. These surgical techniques 
have been considered safe or very low risk but around 1987 the American society of 
plastic and recostrutive  surgeons began to raise doubts about the safecty of these.[72-
73] 
Cancer stem cells (CSCs) Recent experimental evidences have showed that the 
tumorigenic capacity resides only in a small fraction of cells able to sustain the tumor 
growth, called cancer stem cells (CSCs).[77-78] As well as normal tissues, tumors are 
constituted by a highly heterogenic cell population organized as unidirectional 
cellular hierarchies in which CSCs constitute a biologically unique subsets of cells, 
distinguished by their exclusive ability to perpetuate the growth of malignant cell 
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population. CSCs have share several important properties, among these we find 
include the capacity for self-renewal, the ability to differentiate,  active telomerase 
expression, activation of anti-apoptotic pathways, increased membrane transporter 
activity and the ability to migrate and metastasize. One of the key early events in 
transformation may be the dysregulation of the normally highly regulated process of 
self-renewal. In the steady state, stem cells undergo to asymmetric divisions in which 
a stem cell is able to produce an exact copy of itself as well as a daughter cells that 
undergoes differentiation into lineages found in differentiated tissue.[79-81] Gene 
mutations responsible of this balance in normal tissues can give rise to the formation 
of partially differentiated cells constituting the heterogeneous tumor mass. Cancer 
cells in tumors undergo additional genetic or epigenetic changes and interact with thei 
microenvironment, leading to a constant changing variety of tumor cell types within a 
single neoplasm, for example the acquisition of migratory phenotype through the 
Epithelial-mesenchymal transition (EMT) or in the opposite direction through the  the 
Mesenchymal to epithelial transition (MET). Within the primary tumor mass, CSCs 
through their ability to trans differentiate and  their plasticity are able to move and 
migrate within the body, invading distant organs and forming metastases. [82] 
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Results 
breast cancer stem popularion 
We isolated the breast cancer stem cells (BCSCs) from fresh tissue derived from 
mastectomy patients that are undergone by enzymatic and mechanical digestion, as 
previously described [Todaro et al  2007]. The digest single cell suspension was 
plated in ultra low attached flasks and grown in stem cell medium supplemented with 
bFGF and EGF. So, we characterized our BCSCs, following the breast cancer stem 
guide lines established by scientific literature. We characterized the BCSCs by 
immunofluorescence and flow cytometry analysis. (Fig 1) 
 
 
 
 
Figure 1.  Breast cancer subtypes: morphologic and biologic characterization 
(A) Representative confocal microscopy images of immunofluorescence (IF) analysis of  Cytokeratins 
(CK5, CK14, CK8-18), MUC1 and Vimentin  performed in luminal  and Basal BCSCs. (B) Flow 
cytometry analysis of CD44, CD24, CD10, and CD49f expression  in  luminal and basal BCSCs.  
A 
B 
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Different adipose cells cultures release proinflammatory, pro 
angiogenic and pro metastatic cytokines. 
To evaluate the adipocytokines secreted by the different adipose stem culture cells 
and their adipocytes derived we plated ADSCs, ASphCs and their derived cultured 
cells. Then the cell culturing media thus obtained was analyzed by a Elisa luminex 
analysis for the presence of specific growth factors or cytockines. The luminex 
system combine the flow cytometry with the xMAP® microspheres fluorescently 
dyed Technologies. The system enables simultaneously  identify and measure up to 
100 analytes in a single microplate well. The analysis showed that ASphCs and 
ASphC-Derived adipocytes compared to adipose tissue undigested (SVF) (routinely 
used in lipofilling techniques) possess a similar profile of secreted cytokines, even if 
at lower concentration. In particular they express a high concentration of all those 
proinflammatory adipokines, as IL8, IL6, IL12, IFNγ, TNFα, MCP1and RANTES, 
and moreover they secreted an high levels of proliferative cytokines such as LIF and 
GCSF. The analysis then showed how there is even a considerable production of 
those cytokines which can promote angiogenesis and metastasis such as VEGF, SCF 
,PDGF and HGF,MIF and SDF. Contrary in the medium secreted from adipose cell 
cultures the anti-inflammatory cytokines are barely expressed, such as the IL10, IL13, 
IL1ra and IL4. (Fig 2) 
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Figure  2. ASphCs and mature adipocytes compared to undigested adipose tissue (SVF) possess a 
comparable inflammatory,proliferative and angiogenesis Adipocytokines  pattern. 
Paracrine factors secreted by adipose-mesenchymal stem cells cultures, mature adipocytes  and stromal 
vascular fraction (SVF). Data are mean ± SD of four independent experiments using cells from 
different patients. Whiskers: Vmin, Vmax (log10) 
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Adipose mesenchymal stem cell and mature adipocytes accelerate 
breast cancer growth by adipocytokines production. 
To test the breast cancer cell viability and proliferation rate we have tested the 
viability assay using CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(MTS) following the manufacturer’s instructions. This proliferation assay is a 
colorimetric method to determine the number of viable cells in proliferation. The 
experiments performed have shown that the luminal BCSC treated with the different 
adipose conditioned media (the ASphCs and mature adipocytes derived cultured 
cells) acquired a higher cell viability and increase the number of viable cells for the 
increased activity of mitochondrial dehydrogenases which leads to the increase of the 
amount of dye formazan formed. The assay further highlighted that the proliferative 
conditioned medium effect is appreciable just in the 24/48 hours, whereas it is not 
significant in the 72h after exposure. (Fig 3 A-B). To further confirm our results, we 
have performed a PKH26 dye (Sigma-Aldrich) proliferation assay and a soft agar 
colony forming assay. The luminal and basal BCSCs were plated in presence of 
ASphCs and adipocytes derived cultured cells media for 72h. Both assays have 
highlighted how the adipose conditioned media induce greater proliferation rate just 
in luminal BCSCs, instead basal ones do not undergo the effect of adipose 
conditioning. (Fig 3 C-D)  
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Figure 3. Luminal BCSCs treated with Adipose conditioned medium increase their proliferation 
rate and enhance their colonies form ability  
(A-B)  MTS proliferation assay performed in luminal and Basal BCSCs exposed to adipose 
conditioned  media. (C) Soft agar colony forming  assay of  BCSCs tretated as in (A). (D) 
Representative PKH26 flow cytometry analysis of BCSCs labelled with PKH-26 at day 0 and after 24h 
and 48h. 
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Paracrine factors from adipose mesenchiymal stem cells enhance metastatic 
capacity in breast cancer stem cells 
To evaluate the acquisition of a metastic capacity by BCSCs treated with the above 
cited adipose conditioned media, we have performed an invasion assay by using 
polycarbonate membrane filters with a diameter of 6.5 mm and pores with the size of 
8μ. In the upper chamber were plated our BCSCs pretreated with conditioned media, 
and DMEM medium comprising 10% human AB serum added as chemioattrattante  
in the lower chamber. We have observed that luminal BCSCs samples acquired a 
invasive phenotype. (Fig 4 A-B). Further, we investigate the BCSCs migratory ability 
through a scratch assay. We observed the BCSCs migration to 48h. Both luminal and 
basal BCSC showed increased migratory capability when exposed to conditioned 
medium  from both ASphCs and adipocytes (Figure 4 C-D) 
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Figure 4. Adipose conditioned luminal BCSCs acquire a metastatic potential and improve  
migratory ability. 
(A)(B) Invasion assay of BCSCs treated with adipose conditioned media(C-D) BCSCs migration 
analysis in the luminal cell subset (C) and in  basal cell subset (D).  
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Adipose conditioned medium promote an epithelial-mesenchymal 
transition in luminal breast cancer stem cells 
In order to assess a potential gene expression profile changes  in our breast cancer 
samples due to the presence in the culture of the adipocyte conditioned medium we 
have performed the human cancer pathway with RT
2
 profiler PCR array. The gene 
expression analysis highlighted that both luminal and basal BCSCs when exposed to 
conditioned medium of ASphCs and adipocytes changed the expression of several 
important genes involved in the acquisition of a metastatic phenotype. In particulary 
the luminal BCSCs  showed an overexpression of MIKI67 and CDC20 (cell cycle), 
CCL2, FGF2, KDR and ANGPT1 (angiogenesis) MAP2K and SOD1 ( senescence), 
whike in basal ones showed an overexpression of FGF2(angiogenesis)IGFBP3 ang 
SERPINB2 (senescence), SNAI2 (EMT), DDT1 ( DNA damage & repair) HMOX( 
hypoxia signaling). Different results were obtained when BCSCs were treated with  
adipocytes conditioned medium. A lot of genes involved in metastatic processes, 
proliferative and DNA damage repair angiogenic were overexpressed. In particular  
luminal BCSC showed an overexpression of CK14, SNAI2, SOX10, GSC and 
FOXC2 (EMT); KDR,VEGFC, ANGPT1 and FGF2 (angiogenesis); MIKI67, CDC20 
and STMN1 (cell cycle), ERCC5 (DNA damage & repair), SERPINB2 and SOD1 
(senescence).(Fig 5 A-D). The phenotypic swtich of luminal BCSCs toward a basal 
behaviour is confirmed by immunofluorescence analysis. (Fig 5 E) 
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 Figure 5. Exposure to the adipose conditioned medium adipose induces a switch genotype and 
phenotype from luminal to basal in BCSC 
(A)(B) Scatter plot of human cancer pathway in luminal BCSCs treated with ASphCs medium in (A) 
and with mature adipocyte conditioned  medium in (B) (C)(D) Scatter plot of human cancer pathway 
in basal  BCSCs treated with ASphCs medium in (A) and with mature adipocyte conditioned  medium 
in (B). (E) Representative confocal microscopy images of immunofluorescence (IF) analysis of  
Cytokeratins CD10, MUC1 and Vimentin  performed in luminal and Basal BCSCs. 
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Conclusion  and future experiments 
Several scientific papers said that the use of autologous filler in lipotransfer 
techniques not represent for the mastectomized patients a real risk for cancer 
recurrence, and therefore this surgical techniques have been considered safe or very 
low risk, but about 1987 the American society of plastic and reconstrutive  surgeons 
began to raise doubts about the safecty of these. In fact,  recent other studies have 
investigated a possible long-term risk in the use of autologous fillers, and highlighted 
a potential risk for those subjects in which it was removed breast cancer. Hence, the 
elusive role of autologous filler in breast tumor development causes the safety 
concerns their clinical utilization. Therefore, starting from this uncertainty about the 
precise role of adipose tissue on tumor growth, this study, according to the many data 
in the literature concerning the close relation between the microenvironment and the 
relative tumor behavior, assumes that the autologous adipose tissue lipotransfer may 
influence a possible cancer relapse. Thus this work aims to shed light on all the 
possible mechanisms behind this harmful interaction. Furthermore, referring to some 
data in the literature which identify the mature adipocytes and not the pre adipocytes 
as the real responsible for the tumor return or its higher progression, we want to 
investigate the role of a adipose stem cells population, obtained by lipoaspirate 
samples digestion  , identified as the real adipose stem cells, able to grow in non-
adherence conditions in the form of spheroids, in a quiescent cell cycle state and  that 
possess a great multidifferentation ability. This specific adipose stem cells 
population, appropriately characterized and analyzed by comparing with the  adipose 
stem cells already described in the literature, were used for the co-culture studies 
together with breast cancere stem cells, these last considered the real makers of 
cancer chemotherapy resistance and minimal residual disease. Co cultures 
experiments have been preceded by a deep analysis of all the cytokines, adipokines 
and paracrine factors secreted into cell adipose culture medium. The conditioned 
medium analysis showed that adipose stem cultures secrete a cytokines and paracrine 
factors pattern decisively pro inflammatory, angiogenic, proliferative and migratory, 
although with a adipokines concentration less concentrated than the ones secretd by 
mature adipocyte cell populations and  than the undigested adipose tissue which is 
normally used as autologous fillers surgery. Thus breast cancer stem cells were 
cultured in the presence of the adipose stem cells conditioned medium and also in 
presence of mature adipocytes conditioned medium for a specific time. BCSCs 
treated with adipose conditioned media have highlighted the acquisition of a more 
aggressive phenotype. Luminal BCSCs are especially responsive to treatment with 
different adipose conditioned media, infact they acquire a much higher proliferative 
rate and showed a invasive capacity not proper of luminal phenotype, moreover at the 
genotype and phenotype level they seem undergo a partial switch from  luminal to 
basal phenotype. Therefore exposure of BCSC to adipose stem cells and adipose cells 
mature secretome seems to be so critical and highly detrimental, as documented in the 
recent scientific papers. Moreover, even if the adipose stem cells conditioned medium 
contribution seem to be less than conditioned medium released by mature adipocytes, 
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in our opinion it does not seem safe the use adipose autologous fillers enriched of 
adipose stem cell populations or with pre adipocytes. According to our study, in fact, 
the microenvironment that is generated into the operation site after lipotransfer, is a 
dangerous proinflammatory, proliferative and angiogenic microenvironment, which 
could stimulates  the awakening of the few cancer stem cells remained after cancer 
mass surgical removing . So at the moment the best possible advice to overcome the 
mutilation trauma, due to demolitive surgery, is the use of others fillers such as the 
alloplastic fillers, some scaffolds or any more inert implants than autologous fillers. 
As future prospects it could be the evaluation through the same coculture system the 
same data obtained from in vitro experiments also through  in vivo model 
experiments. The BCSC tumorigenicity will be determined via subcutaneous 
injection BCSCs,  conditioned or not treated with adipose medium, into the fat pad of 
5 week-old NOD/SCID mice. After that we would investigate the possibility to 
ingegnerize the autologous filler with some ectopic factor, that could regulate the 
secretion or the prolifrative action possessed by the adipose stem cells. 
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Materials and Methods  
Tissue collection and cell culture  
Fresh tissue acquired from mastectomies of 8 patients (age 40–89) were collected at 
the University of Palermo and Fondazione IRCCS INT of Milan, in accordance with 
ethical standards. Breast tumor cells were purified from fresh tissue via enzymatic 
digestion as previously described [48]. Thereafter, single cell suspensions were plated 
in ultra-low attachment flasks (Corning) at a density of 1×10
5
/ml
 
and grown in a 
medium supplemented with bFGF (10 ng/ml, Sigma) and EGF (20 ng/ml, Sigma). To 
induce differentiation, cells were cultured in adherent conditions in Ham’s/F-12 
medium (Euroclone), supplemented with 5% fetal bovine serum (FBS), insulin 
(25μg/ml, Sigma) and hydrocortisone (1mg/ml, Sigma). MCF7 cells were purchased 
from ATCC and cultured in DMEM  supplemented with 10% fetal bovine serum 
(Sigma). Adipose tissue was extracted from a lipoaspirate and subcutaneous breast 
tissue biopsy of 50 patients (16 males; 34 females) in compliance with our 
Department’s policy and following patient’s written consent on adipose tissue harvest 
and its use for research purposes. Patients ranged from 20 to 65 years of age and all 
selected donors were healthy and without a prior history of malignancy. Tissues were 
obtained either from subcutaneous adipose tissue or during liposuction of the 
abdominal or inner thigh regions using Coleman’s cannulas, following infiltration 
with Klein’s solution (NaCl 0.9%; lidocaine 2%; epinephrine 1:1000; NaHCO3 
8.45%). Approximately, 20 cc of lipoaspirate and 0.05±0.02 gr tissue biopsies were 
collected from each patient and directly transferred to tissue culture tubes for 
enzymatic digestion and stem cell purification. Breast-derived Adipose tissue and 
lipoaspirate samples were digested with collagenase (1.5 mg/ml, GIBCO) and 
hyaluronidase (20 mg/ml, Sigma) through gentle agitation for 30 minutes at 37°C. 
The digested sample was centrifuged at 1200 rpm for 5 min and the recovered cells 
(Freshly) were plated with serum-free stem cell-specific media as previously 
described [59]. Cells were plated in stem cell medium in presence of  bFGF (10 
ng/ml, Sigma) and EGF (20 ng/ml, Sigma), in ultra-low adhesion tissue culture flasks 
(Corning) and placed at 37°C in a 5% CO2 humidified incubator. In these conditions, 
cells grew as floating spheroids (ASphCs). Part of the isolated cells were plated in 
adherent conditions (DMEM+FBS 10%) and were referred as primary culture 
(Primary). Conversely, we termed ADSCs the commercially available STEMPRO® 
Human Adipose-Derived Stem Cells, plated as recommended by the manufacturer 
(Invitrogen). To evaluate ASphC multilineage differentiation capacity, 5x10
3
 single 
cells were diluted 1:4 in a cold Matrigel solution (growth factor reduced BD). This 
solution (50 µl/well) was dispensed into pre-warmed 24-wells plates and let 
polymerize for 30 minutes at 37°C. Finally, the wells were filled using 700 μl/well of 
basal culture medium. 
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Osteogenic, Adipogenenic and Chondrogenidifferentiation 
Briefly, ASphCs and ADSCs were trypsinized 1 min at 37°C and plated into 24-well 
cell culture plates (50.000 cells/well). Cells were allowed to adhere and cultured in 
the STEMPRO® Osteogenesis Differentiation Kit, STEMPRO® Chondrogenesis 
Differentiation Kit (Invitrogen (Invitrogen) and STEMPRO® Adipogenesis 
Differentiation Kit (Invitrogen) up to 28 days. Cell viability, adhesion and 
differentiation was assessed by daily observation using an optical microscopy. 
Osteogenic differentiation was assessed by performing a staining for alkaline 
phosphatase activity (ALP) (BCIP/NBT alkaline phosphatase substrate kit, Vector 
Laboratories), osteopontin (OPN) (polyclonal rabbit, Sigma-Aldrich) or von Kossa 
for calcium deposition (Polysciences Inc.). Chondrogenic differentiation was assessed 
by alcian blue. Briefly, the sample was fixed in 2% PFA for 30 min at 37°C, washed 
in PBS and incubated with alcian blue for 30 minutes. Cells were then counterstained 
with nuclear fast red for 5 minutes. Adipogenic phenotype change assessed by 
adipored assay (Lonza) for 10 min at room temperature. Nuclei were counterstained 
with Toto3 and the staining was observed using a confocal microscope. 
Flow cytometry 
Adipose stem cells were stained with conjugated antibodies against CD44-FITC 
(G44-26, mouse IGg2bk, BD), CD271-ALEXA FLUOR 647 (C40-145, mouse 
IgG1k, BD), CD90-PE (5E10, mouse IgG1k, BD), CD45-FITC (5B1, mouse IgG2a, 
Miltenyi), CD19-ALEXA FLUOR 488 (HIB19, mouse IgG1k) or with purified 
primary, CD29 (MAR4, IgG1k, BD), CD73 (AD2, mouse IgG1k, BD), CD9 (ML13, 
mouse IgG1k, BD). Then, cells were labeled with goat anti-mouse IgG FITC 
secondary antibody (Invitrogen). BCSCs were exposed to primary antibodies CD44 
(BU75, Ancell), CD24 (ML5, R&D System), CD10 (FR4D11, Santa Cruz 
Biotechnology), CD49f (GoH3 Miltenyi Biotec), EpCAM (AF960, R&D System) or 
corresponding isotype controls, rinsed and labeled with secondary antibodies. BCSCs 
were stained with CD49f and CD24 and successively sorted via flow cytometry using 
an FACSAria cell sorter (BD Biosciences). The analysis of ALDH1 activity was 
performed using the ALDEFLUOR kit (StemCell Technologies). For cell cycle 
analysis, BCSCs were fixed in 70% ethanol and incubated with 50 μg/mL propidium 
iodide (Sigma-Aldrich), 3.8 mmol/L sodium citrate (Sigma) and 10 μg/mL RNase 
(Sigma). Specific corresponding isotype matched antibodies were used as negative 
controls. Samples were acquired using a FACS ARIA (BD Biosciences) flow 
cytometer. All data were analyzed using FlowJo software (Tree Star). 
Gene expression 
Total RNA was extracted by using a RNeasy Mini Kit (Quiagen) and 1 µg of each 
sample was retro-transcribed into cDNA using a high-Capacity cDNA Reverse 
Transcription Kit as recommended by manufacturer (Applied Biosystems). 
Expression of mesenchymal stem cell genes and expression of human cancer pathway 
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was performed through RT
2
 profiler PCR array (PAHS-082ZR and PAHS-033Z 
Quiagen), according to manufacturer's instructions. Arrays were performed for 
ASphCs, ADSCs and their differentiate cells, and for luminal and basal BCSCs. At 
least 2 replicates were run for each sample. ).  
Cell cycle and proliferation assay 
Cell cycle analysis was performed on dissociated cells by staining with 50 µg/ml 
propidium iodide (Sigma-Aldrich) dissolved in buffer 0.1% sodium citrate (Sigma-
Aldrich), 0.1% Triton X-100, 10 µg/ml RNAse (Sigma-Aldrich) for 1h on ice. 
Samples were acquired through a FACS Calibur flow cytometer (BD Biosciences). 
The proliferation assay was evaluated by using PKH26 dye (Sigma-Aldrich). 20x10
4 
of dissociated cells were stained for 1 h at 37°C with PKH26 according to 
manufacturer’s instructions, then washed extensively with PBS and cultured for 14 
additional days. PKH26 red fluorescence was analyzed by FACS Aria flow 
cytometer. All data were analyzed using FlowJo software. Evaluation of ASphC, 
ADSC, luminal and basal BCSCs proliferation was assessed using CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (MTS) according to the 
manufacturer’s instruction. 
Immunofluorescence 
BCSC were cytospun at low speed on polylysine-coated glass slides  BCSCs were 
fixed with 2% paraformaldehyde for 30 minutes at 37°C and permeabilized in 0.1% 
Triton X-100 (Bio-Rad Laboratories, Richmond, CA, http://www.bio-rad.com) and 
incubated O.N. at 4°C with the following primary antibodies: ALDH1 (44, BD), CK5 
(XM26, Novocastra), CK14 (LL002, Novocastra), CK8-18 (CD10, Novocastra), 
MUC1 (BD Pharmigen), VIMENTIN (R28, Cell Signaling), ER (6F11, Novocastra). 
After two washes in PBS, cells were incubated with Alexa Fluor-conjugated 
secondary antibodies(Invitrogen) for 30 minutes at room temperature in the dark. 
Nuclei were counterstained with Toto-3 (Invitrogen). Slides were analyzed on a 
FV1000 confocal microscope (Olympus, Tokyo, Japan, http://www.olympus-
global.com) equipped with x60 and x40 oil immersion objectives. 
Luminex  
Cytokines Quantification Quantification production was assessed by using multiplex 
Bio-Plex Pro Assays (Bio-Rad; Human Cancer Biomarker Panel 1-4 No. 171-
AC500M; Human Cytokine SDF-1a Set No. 171-B6019M; TGF-b 3-plex Assay No. 
171-W4001M). Raw data (mean fluorescent intensity) from all kits were analyzed by 
Bio-Plex Software (Bio-Rad). 
Migration and Invasion assay 
Transduced and control BCSCs were seeded into six-well plates at a density of 1x10
6
 
cells/well and cultured to achieve a confluent cell layer in culture medium. The day 
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after, the growth medium was switched to serum-free medium for 16 h, after which a 
sterile 200 µl pipette tip was used to straight scratch a constant-diameter stripe in the 
confluent cell monolayer. The wells were then washed with 1 ml of PBS to remove 
detached cells and debris and the medium was replaced using a fresh culture medium. 
Wound healing was visualized by following the migrating cells in the gap during a 
24-h post-scratch period using the EVOS™ fl Digital Inverted Fluorescence 
Microscope with a 10X objective. 
Cells tested for invasive potential (2x10
3
) were plated into Matrigel-coated (BD) 
transwells of 8 µm pore size (Corning), into a 24 well plate. DMEM supplemented 
with 10% human serum (600 µl/well) was used as chemo-attractant in the lower 
chamber of the transwell. Migration was observed and counted microscopically for 72 
hrs. 
Statistical Analysis 
Data are explicited as mean ± standard deviation (SD). Statistical significance was 
calculated by applying Student’s t-test. Significance levels were indicated as p values. 
* indicates P<0.05, ** indicate P<0.01 and *** indicate P<0.001 
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A preliminary study  
 
The miRNAs contribution in the adipocyte maturation 
 
Introduction 
MiRNA 
miRNAs  discovery, which occurred only in 1993 by the group of Dr. Victor Ambros, 
is one of the most revolutionary scientific discoveries for the cell biology and 
medicine.  MiRNAs reppresent a class of  small endogenous single stranded non-
coding RNA molecules on the size of about 18-25 nucleotides deputies to a negative 
gene expression regulation after transcription by binding to specific mRNAs 3'UTR 
and mediating its degradation or translational repression [1] (Figure 1) 
 
 
 
Figure.1: Graphical representation of the hybridization site of a mRNA target 
 
Experimental evidence indicate that miRNAs play a key role in the control of various 
biological activities such as embryonic development, cell proliferation, metabolic 
homeostasis and apoptosis [2]. Computational analyzes indicate that genes coding for 
mRNA represent approximately 1% of the genome of different species. Along with 
Small interfering RNA (siRNA), Piwi RNA (piRNA), Trans-acting siRNA 
(tasiRNA), Small-scan RNAs (scnRNA) and repeat-associated siRNAs (rasiRNA) are 
part of the class of small RNA. [3] Since the RNA interference discovery have been 
made many efforts in trying to characterize these endogenous molecules and which 
have led to the identification of hundreds of miRNAs in different model organisms 
[4]. To date it has been identified about 1,000 different genes coding for miRNAs. [3] 
The miRNAs genes are distributed on all human chromosomes except the Y 
chromosome and in 50% of cases are organized in clusters and involving a 
polycistronic primary transcription [5]. Initially it was believed that most of these 
genes were located in an intergenic region [6-7], but recent studies have shown that 
genes coding for miRNAs are present in transcriptionally active regions [8], and in 
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particular most of these are found in intron sense, introns coding for proteins and in 
low percentage in exonic regions. For these reasons miRNAs are classified in intronic 
miRNAs protein-coding, non-coding intronic miRNAs and esonic non-coding 
miRNAs [3]  
 
miRNA Biogenesis and Processing 
The mature miRNA precursors come from the largest genome transcribed by RNA 
polymerase II as a primary miRNA variable size of approximately 100 nucleotides 
and as others have transcribed the hood and is polyadenilato [9-10]. This is followed 
by the maturation of the pri-miRNA processing through two passages in which they 
are involved two ribonuclease Class III: Drosha and Dicer. Ribonuclease Drosha 
together with its partner protein Dgcr8 processes the pri-me-nuclear RNA in a 
precursor molecule pre-mi-RNA of about 70 nucleotides [11-15]. This is exported 
from the nucleus to the cytoplasm by the action of Esportina5 that recognizes 
specifically the structure of pre-miRNA [16-18]. Once in the cytoplasm, the pre-
miRNA is processed by the second enzyme Dicer ribonucleotidico together with the 
protein TRBP (Trans activator RNA BindingProtein) in the form duplex of about 21 
nucleotides, where one strand is linked selectively to the enzyme complex RISC 
silencing. Recently it has been proposed in Caenorhabtis elegans and Drosophila 
melanogaster an alternative pathway independent of Drosha where a small hairpin 
intronic undergoes splicing in the form of pre-miRNA defined mintroni able to enter 
the miRNA biogenesis without the mediation of action processativa Drosha. RISC 
recognizes the miRNA target thanks to miRNA that has '' loaded '', thanks to a partial 
complementarity between miRNA and mRNA target. The binding sites for miRNAs 
thus far described are located at the level of the 3'UTR (although recent studies have 
demonstrated the presence of binding sites for miRNAs also in the coding regions). 
The interaction requires the formation of a double-stranded structure between bases 
from second to eighth in the miRNA region called '' seed '', and the target mRNA. To 
date it has been proposed several mechanisms of action for miRNAs, among the 
mechanisms there is the most accepted model cleavege mRNA and that of the 
translational repression [19-20] (Figureure 3). Other proposed mechanisms of 
repression include: inhibition of ribosome binding to the mRNA target, the 
kidnapping and deadenilazione messenger cytoplasmic bodies defined in P-bodies 
(Eulalio et al. 2008). 
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Figure.3: Biogenesis and function of miRNAs (Kaleb M.,Ann.N.Y. Accad.Sci,2008). 
 
Mirnas and cancer 
In recent years, the list of oncogenes or tumor suppressor genes considered was 
revised, expanding the latter to the family of miRNAs [21-22]. Depending on the 
capabilities we distinguish the oncomiR, which are located in regions amplified and 
over expressed in the tumor, and the tumor suppressor miRNAs, down regulated in 
tumors [23-24]. A study published in PNAS in 2004 showed that about 50% of 
human miRNAs are located in genomic regions frequently rearranged tumors: fragile 
sites, delete regions (minimal region of loss of heterozigosity, LOH) or amplified 
(minimal amplicons) and regions common break-point, providing further evidence of 
their role in the pathogenesis of cancer [25-26]. (Figureura 4) 
 Examples oncomiR are miR-155, amplified in many hematological malignancies 
such as Burkitt's lymphoma, lung cancer and breast cancer. The miR-17-92 cluster 
that includes 6 genes for miRNAs overexpressed in solid tumors and lymphoma 
diffuse large B-cell Among the tumor suppressor miRNAs were characterized miR-
15a and miR-16-1, deleti in chronic lymphocytic leukemia , that target the 
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antiapoptotic protein BCL2, and the let-7 family, that represses the expression of the 
oncogene RAS. Other experimental evidence have also shown that the expression of 
protein processing in the biogenesis of miRNAs such as Dicer, RISC, Argonaut are 
respectively iporegolati in cases of lung cancer, Wilms tumors (kidney) and 
neuroendocrine tumors. The list of miRNAs involved in the tumorigenic processes is 
increasing in frequency. On the basis of the characteristics described above, the 
miRNA can therefore be considered good target for anti-tumor therapy. In fact the 
introduction of the miRNA or dell'antagomiR in tumors in which this has been lost or 
is overexpressed can lead to the arrest of the cell cycle and / or apoptosis. 
 
 
Figure.4: List of some oncomiRNA and tumor suppressor miRNAs and related cancers in which 
involved (G. Calin et al. PNAS, 2004). 
 
microRNAs in the Regulation of Adipogenesis 
Several studies have reported a screening miRNA changes during adipogenic 
differentiation of human multipotent mesenchymal stem cells, and many of these 
studies demonstrated miRNAs are very important players in human MSCs adipogenic 
lineage commitment. [28-33]. In recent years, there has been a rapidly growing 
interest in the role of miRNAs in fat cell development and obesity [34-35]. Studies 
have showed miRNA expression in pre-adipocytes is altered during adipose tissue 
development and in obesity, therefore a better understanding of the pathways 
controlling adipogenesis is needed. Fact understanding the role miRNAs play in the 
proliferation and differentiation of adipocytes during fat cell development could 
provide new therapeutic targets.  There are miRNAs can accelerate adipocyte 
differentiation, such as miR-143, that was the first miRNA associated with regulation 
of adipocyte differentiation, its expression increases in differentiating adipocytes, and 
antisense oligonucleotides against miR-143 inhibit human-cultured adipocyte 
differentiation downregulate PPARγ and GLUT-4. Several other miRNAs have been 
identified which can accelerate adipocyte differentiation (including miR-103, miR-
107 and miR-143) are induced during adipogenesis, which may play a role in 
accelerating adipocyte differentiation, and then be downregulated in the obese state. 
One study demonstrated ERK5 (Extracellularsignal- regulated kinase 5) is targeted by 
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miR-143 in human pre-adipocytes [29]. The role of ERK5 in adipocyte differentiation 
is not clear, although it has been suggested ERK5 suppression may be involved in 
fine-tuning the MAPK (mitogen activated protein kinase) pathway to maintain the 
differentiated state. miR-103 is reported to be upregulated during differentiation of 
human pre-adipocytes, and its overexpression in the presence of adipogenic stimuli, 
adipogenesis accelerates, as shown by increased triglyceride accumulation and 
adipogenic gene expression. [36-41]  
Another adipogenic miRNA to emerge recently is miR-210, which is a key 
transcription factor modulating components of WNT signaling. Overexpression of 
miR-210 is reported to stimulate adipocyte hypertrophy and lipid droplet formation. 
The upregulation of miR-210 during adipogenesis is in concordance with a 
suppression of genes encoding proteins in the WNT signaling pathway [42].  Any 
others miRNAs, such as miR-221, miR-125b, miR-34a and miR-100, were 
upregulated in fat depots from obese subjects and downregulated during adipocyte 
differentiation.  miR-34a was found to be positively upregulated during adipogenesis 
and associated positively with BMI (Ortega et al. 2010 ). Others miRNAs CAN 
suppress adipocyte differentiation.Some studies have focused on miRNAs which 
appear to act as negative regulators of adipocyte differentiation. miR-27a 
overexpression in pre-adipocytes suppresses PPARγ expression and adipocyte 
differentiation [43]. Another family member, miR-27b is also downregulated during 
adipocyte differentiation. MiR-27b can also bind to the 3’UTR of PPARγ and repress 
PPARγ protein levels [31].  Interestingly,in mature adipocytes from obese mice lower 
miR-27a expression has been found compared to lean mice, indicating miR-27a 
downregulation may be necessary for adipocyte hypertrophy [44]. These studies 
suggest the miR-27 family could be a useful anti-adipogenic target. Potentially miR-
27a mimics could be used to regulate pre-adipocyte proliferation. Another study 
reported miR-448 is a potential inhibitor of adipogenesis. miR-448 is encoded within 
the intron of HTR2C, a serotonin receptor which is upregulated during adipocyte 
differentiation. Kruppel-like factor 5 (KLF5) contains a putative miR-448 binding 
site. Overexpression of miR-448 in pre-adipocytes suppresses KLF5, triglyceride 
accumulation and adipogenic gene expression thus suggesting miR-448 is a negative 
regulator of adipocyte differentiation [45]. Inhibition of miR-15a appears to reduce 
preadipocyte size while promoting adipocyte proliferation. In preadipocytes miR-15a 
has been shown to target DLK1 at mRNA and protein level. Inhibition of miR-15a in 
pre-adipocytes resulted in a decrease in cell size along with an increase in cell number 
[46]. Furthermore, miR-222 and miR-221 are decreased during adipogenesis but 
upregulated in obese adipocytes, contrary, miR-185 was upregulated in mature 
adipocytes while downregulated in obese men.  
In summary, to date studies have identified several candidate miRNAs which can 
accelerate or inhibit preadipocyte differentiation . These miRNAs may provide 
promising candidates to design anti-obesity drugs to control fat cell development. 
However, it remains important to examine whether miRNAs which regulate 
adipocyte differentiation in-vitro are dysregulated in human obesity in-vivo.  
68
 Aims of work  
 
Tthis study is  would to identify through a depth screening of many of the best known 
miRNA described by the scientific literature, which of them are overexpressed in 
adipose stem cells and in mature adipocytes. In fact many of miRNA present in our 
analysis have been widely described as master regulators of many fundamental 
biological processes such as senescence, proliferation the severance and therefore 
may be involved in disease processes such as cancer and obesity. Moreover it is also 
made extensive use of autologous adipose tissue as filler in aesthetic surgery 
applications and regenerative medicine, in order to reshape anatomical defects or 
exploiting the great capacity multi differentiation proper of mesenchymal stem cells 
which results in improvement of tissue regeneration. Several scientific works have 
investigated about a possible long-term risk in the use of autologous fillers, and these 
papers highlighted a tumoral recurrence potential risk for those subjects in which it 
was removed a previous tumoral mass. Hence, the elusive role of  adipose autologous 
filler in causes the safety concerns their clinical utilization also in other surgical 
applications. Therefore, according to the many data in the literature concerning the 
close relation between the adipose microenvironment and  many pathologies, and  
furthermore, referring to some data in the literature which identify the mature 
adipocytes and not the pre adipocytes as the real responsible for the enhancing tumor 
progression and obesity this work aims to shed light on all the possible mechanisms 
behind this harmful interaction.  In partiulary we want to investigate if  there are some  
miRNAs overexpression in a one specific adipose stem cells population, obtained by 
lipoaspirate samples digestion  , identified as the real adipose stem cells, that are able 
to grow in non-adherence conditions in the form of spheroids, in a quiescent cell 
cycle state and  that possess a great multidifferentation ability, and  also in the mature 
adipocytes derived from the above citated adipose stem population, which could be 
manipulated to achieve an improvement in all those clinical applications currently in 
use. To this end,  we are looking for oncomiRNA, miRNA tumor suppressor, miRNA  
involved in osteogenic maturation, and of those miRNA regulating adipocyte 
maturation. 
 
.  
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Figure 6 . Evaluation of miRNAs expression in the primary and adipose derived cultures. 
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(A) ASphCs human micro RNA expression comparerd to ADSC. (B) ADSC human micro RNA 
expression compared to ADSC-Derived Adipocytes (ADA). (C) ASphCs  human micro RNA 
expression compared to ASphC-Derived Adipocytes (SDA). 
Figure  5 Scatter plot of human MicroRNA ecpressed in  inASphC, ADSC  and marure 
adipocytes derived from ADSC (ADA) and ASphCs (SDA). 
(A) Scatter plot of   ASphCs micro RNA expression comparerd to ADSC. (B) Scatter plot of  ADSC 
compared to ADSC-Derived Adipocytes (ADA). (C) Scatter plot of  ASphCs  compared to ASphC-
Derived Adipocytes (SDA). 
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 Materials and Methods  
Adipose tissue samples and cell culture  
Adipose tissue was extracted from a lipoaspirate and subcutaneous breast tissue 
biopsy in compliance with our Department’s policy and following patient’s written 
consent on adipose tissue harvest and its use for research purposes. Tissues were 
obtained either from subcutaneous adipose tissue or during liposuction of the 
abdominal or inner thigh regions. Breast-derived Adipose tissue and lipoaspirate 
samples were digested with collagenase (1.5 mg/ml, GIBCO) and hyaluronidase (20 
mg/ml, Sigma) through gentle agitation for 30 minutes at 37°C. The digested sample 
was centrifuged at 1200 rpm for 5 min and the recovered cells (Freshly) were plated 
with serum-free stem cell-specific media as previously described [47]. Cells were 
plated in stem cell medium in presence of  bFGF (10 ng/ml, Sigma) and EGF (20 
ng/ml, Sigma), in ultra-low adhesion tissue culture flasks (Corning) and placed at 
37°C in a 5% CO2 humidified incubator. In these conditions, cells grew as floating 
spheroids (ASphCs). Conversely, we termed ADSCs the commercially available 
STEMPRO® Human Adipose-Derived Stem Cells, plated as recommended by the 
manufacturer (Invitrogen).  
MIRNA Gene expression  
Total RNA was extracted using a TRIzol® Reagent solution (Ambion) following 
manufacturer’s instructions) and miRNA expression analysis was performed by 
Megaplex pools protocol specific for a set of 384 microRNAs (pool A) as 
recommended by manufacturer (Applied Biosystems). The relative quantification of 
microRNA expression was calculated using the equivalent Ct values where the 
original CT values are projected to 100% target efficiency, all the experiments were 
normalized using global normalization method.[27] microRNA asrays were 
performed for ASphCs, ADSCs and their differentiate cells. At least 2 replicates were 
run for each sample. miRNAs with 3 fold changes were considered for analysis. 
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ABSTRACT
Basal-like breast cancer is an aggressive tumor subtype with a poor response to 
conventional therapies. Tumor formation and relapse are sustained by a cell subset of 
Breast Cancer Stem Cells (BrCSCs). Here we show that miR-100 inhibits maintenance 
and expansion of BrCSCs in basal-like cancer through Polo-like kinase1 (Plk1) down-
regulation. Moreover, miR-100 favors BrCSC differentiation, converting a basal like 
phenotype into luminal. It induces the expression of a functional estrogen receptor 
(ER) and renders basal-like BrCSCs responsive to hormonal therapy. The key role 
played by miR-100 in breast cancer free-survival is confirmed by the analysis of a 
cohort of patients’ tumors, which shows that low expression of miR-100 is a negative 
prognostic factor and is associated with gene signatures of high grade undifferentiated 
tumors. Our findings indicate a new possible therapeutic strategy, which could make 
aggressive breast cancers responsive to standard treatments.
INTRODUCTION
The onset and progression of malignant tumors 
depend on a small pool of tumor cells with biological 
properties similar to those of normal adult stem cells. In 
accordance to this cancer stem cell hypothesis, tumors are 
organized in a hierarchical manner and are characterized 
by cells that exhibit the ability to self-renew as well as to 
give rise to differentiated cells. The CSCs represent the 
apex of this hierarchy and appear to be the phenotypic 
and functional equivalents of normal stem cells harboring 
oncogenic mutations [1]. CSCs have been isolated in most 
human solid tumor types, suggesting their central role in 
tumor development, progression and recurrence [2]. The 
presence of a CSC pool is associated with aggressiveness 
and a negative prognosis in breast cancer patients. CSCs 
are thought to possess intrinsic resistance to current 
conventional therapies as compared to the bulk tumor cell 
population and it has been proposed that tumor recurrence 
is driven by this subpopulation of CSCs [3-5]. 
MicroRNAs (miRNAs) are small non-coding RNAs 
that regulate gene expression at a post-transcriptional 
level, thus monitoring several biological processes. Their 
deregulated expression contributes to cancer development 
and progression and can influence both the response to 
therapy [6] and the development of drug resistance [7, 8]. 
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Recently, miRNAs have also emerged as critical players 
in the maintenance of pluripotency, control of self-renewal 
and cell fate [9]. Restricted miRNA patterns are expressed 
only in Embryonic Stem Cells (ESCs) [10, 11] and specific 
miRNAs regulate and are regulated by key stem cell genes 
[12, 13]. The importance of the miRNA pathway in the 
biology of stem cells has been confirmed in Dicer-1 knock-
out mice, where the loss of Dicer-1 results in the depletion 
of the stem cell population in embryos [14]. Moreover, 
Dicer-1 deficient murine ESCs fail to differentiate [15]. 
The majority of miRNAs that are important in ESC 
biology are also involved in oncogenesis. This fuels the 
hypothesis that miRNAs could be determinant in cell 
stemness both in normal and in cancer stem cells [16, 17]. 
In line with this hypothesis, recent data provide evidence 
that miRNAs might connect stemness and metastasis. 
Indeed, some miRNAs specifically expressed in ESCs 
can be inopportunely expressed in cancer cells, promoting 
epithelial mesenchymal transition (EMT) [18, 19] and 
metastasis [20]. 
The miR-100 family of microRNAs is composed 
of three members, miR-100, miR-99a and miR-99b. 
Comparative studies indicate that miR-100 is the oldest 
known animal microRNA [21] and is widely expressed 
in vertebrates [22]. Recent data demonstrated that miR-
100 is under-expressed in human ESCs compared 
to differentiated cells [23] and is required for proper 
differentiation of mouse ESCs [24]. The role of miR-100 
in cancer is quite contradictory, since it can behave either 
as an oncogene or as a tumor suppressor gene, depending 
on the tumor type [25-27]. 
The present work shows that miR-100 plays a 
pivotal role in regulating the transition between stemness 
and differentiation of Breast Cancer Stem Cells (BrCSCs). 
The ectopic expression of miR-100 in CSCs isolated from 
breast cancer specimens impaired their self-renewal and 
tumor-initiating ability. Notably, miR-100 induced luminal 
differentiation in basal-like BrCSCs and rendered them 
sensitive to endocrine therapies, such as tamoxifen and 
fulvestrant. 
RESULTS 
MiR-100 down-regulation induces a 
mammosphere-like phenotype in breast cancer 
cells
Expression profiling studies showed that miR-
100 is deregulated in various types of cancers [25-27]. 
Here, attention was focused on human breast cancer, 
where the biological role of miR-100 in tumor onset and 
progression remains elusive. The aim was to modulate 
miR-100 expression in vitro in breast cancer cells and 
study the biological consequences. The breast cancer 
cell line MCF7 was transiently transfected in the absence 
of serum, either with a miR-100 specific antagomir or 
a control antagomir. MiR-100 antagomir transfected 
cells acquired a mammosphere-like phenotype. These 
mammospheres retained the ability to differentiate when 
cultured in the presence of serum, acquiring an adherent 
shape (Fig. 1A). In order to ensure that antagomir-induced 
mammospheres showed stem cell characteristics, we 
analyzed the expression of the stem cell transcription 
factors Nanog, Oct4 and Sox2. As shown in Fig. 1B, miR-
100 depleted cells expressed higher levels of the three 
transcription factors, compared to cells transfected with 
the control antagomir and to mammospheres obtained 
from MCF7 cells cultured in standard stem cell conditions. 
A wider gene expression analysis revealed that miR-
100 knockdown led to a global gene reprogramming 
that could be responsible for the acquisition of the 
stem-like phenotype (Fig. 1C). Also employed was a 
complementary approach, evaluating miR-100 expression 
in mammospheres generated from breast cancer cell lines 
cultured in standard stem cell conditions. Consistently, the 
expression of the miRNA was lower in mammospheres 
than in the original adherent cells (Supplementary Fig. 1A, 
B). 
Analysis of miR-100 expression in Breast Cancer 
Stem Cells
The level of miR-100 expression might be critical 
in maintaining stemness and in determining the transition 
from a stem to a differentiated status in cancer cells. 
When miR-100 expression was analyzed in a panel of 
CSCs isolated from basal-like and luminal breast cancer 
specimens (Supplementary Table 1), lower average levels 
of miR-100 were found in the CSCs derived from basal-
like tumors (Fig. 2A). BrCSCs derived from patient 5 (P5), 
classified as basal-like subtype and expressing the lowest 
level of miR-100, were selected for further experiments. 
These cells displayed low levels also of the other two 
members of the miR-100 family, namely miR-99a and 
miR-99b (Supplementary Fig. 2A). The expression of the 
miRNAs in P5 BrCSCs was evaluated upon growth in 
conditions which favored differentiation. As shown in Fig. 
2B and Supplementary Fig. 2B, the level of the miRNAs 
promptly increased upon differentiation. 
MiR-100 impairs self-renewing and tumor-
initiating ability of BrCSCs 
In order to investigate whether miR-100 could 
interfere with the stem properties, an exploration of 
the self-renewing ability of tumor-derived P5 BrCSCs 
expressing stable miR-100 upon lentiviral transduction 
(data not shown) was undertaken. BrCSCs infected 
with a short hairpin scramble encoding lentivirus were 
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used as a control. Exogenous expression of miR-100 
severely impaired the clonogenic activity of BrCSCs in 
in vitro limiting dilution assay (Fig. 3A) and in the soft 
agar assay (Fig. 3B). Similar results were observed in the 
subpopulation of BrCSCs obtained by sorting the bulk 
population for the expression of the breast cancer stem 
cell markers CD49f and CD24 [28, 29] (Supplementary 
Fig. 3A, B). The effect of miR-100 on BrCSC proliferation 
was evaluated via a cell cycle analysis. These data showed 
a reduced G2 phase and an enlarged sub-G1 population in 
miRNA transduced BrCSCs as compared to corresponding 
controls (Fig. 3C). Consistently, an increased apoptotic 
rate was revealed by an enhanced caspase3/7 activity 
(Supplementary Fig. 3C). Labeling of BrCSCs with the 
lipophilic fluorescent dye PKH-26 was used to further 
investigate the effect of miR-100 on self-renewal. PKH-
26 is retained by quiescent stem cells whereas it is 
gradually lost by proliferating progenitor cells [30]. MiR-
100 expression reduced the percentage of PKH-26high 
cells (Fig. 3D, E), leading to the depletion of the BrCSC 
proliferating pool.
CSCs are defined as those cells able to originate the 
tumor and recapitulate the heterogeneity of the original 
tumor mass when implanted in immunocompromised 
mice. This inherent tumor-initiating capacity of CSCs is 
believed to be responsible for tumor relapse in patients. 
To address whether miR-100 could affect tumorigenic 
potential, miR-100 or scramble transduced BrCSCs 
were allowed to orthotopically grow in the mouse 
mammary gland of NOD/SCID mice. Interestingly, 
ectopic expression of miR-100 completely suppressed 
tumor growth (Fig. 4A). Histological examination of 
the fat pads showed that only a few breast cancer cells 
expressing the proliferation marker Ki67 and the stem 
cell marker Aldehyde Dehydrogenase 1 (ALDH1) were 
present in the residual tumor xenografts (Fig. 4B). Similar 
results (Supplementary Fig. 4) were obtained in an 
additional patient-derived basal-like BrCSC model (P8, 
Figure 1: MiR-100 inhibition induces a stem-like phenotype in breast cancer cells. A, phase contrast images of MCF7 cells 
transiently transfected with a control (ctr) or a miR-100 specific antagomir (antag). Following miR-100 antagomir transfection, obtained 
mammospheres retained the ability to differentiate when cultured in DMEM 10% Foetal Bovine Serum (antag 10%FBS 24h; antag 10%FBS 
7 days). Magnification 4x. B, stem cell transcription factors expression in control and antagomir transfected cells, analyzed by quantitative 
RT-PCR. Data are average ± SD of biological replicates. MCF7 cells and mammospheres obtained from MCF7 cells upon growth in stem 
cell conditions (MCFS) were used as controls. * P< 0.05. C, stemness and pluripotency gene expression profiling of the cells described in 
(B) performed using TaqMan gene expression arrays. Gene expression is reported as -∆CT (CT gene – CT GAPDH) median-centered. A, 
B, C and D indicate biological replicates. 
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Figure 3: Ectopic expression of miR-100 in BrCSCs impairs self-renewal. A, percentage of clonogenicity in BrCSCs (P5) wild 
type (wt) and stably expressing either a control scramble (scr) or miR-100. Data are average + SD of 3 independent experiments. ** P<0.01. 
B, colony forming efficiency of BrCSCs transduced as in (A), assessed by soft agar assay (bottom); histogram shows the quantitative 
analysis. Data are average + SD of 3 independent experiments. *** P<0.001. C, cell cycle analysis of wt, scramble or miR-100 stably 
expressing BrCSCs determined by propidium iodide staining. * P<0.05. D, representative phase contrast and fluorescence microscopy 
analysis of wt, scramble or miR-100 transduced BrCSCs labelled with PKH-26 and cultured in soft agar up to 40 days. E, flow cytometry 
analysis and quantification of PKH-26 in cells transduced as in (D), after 14 days of culture. The experiments were performed in triplicates. 
** P<0.01.
Figure 2: MiR-100 expression increases upon basal-like Breast Cancer Stem Cell (BrCSC) differentiation. A, miR-
100 expression in BrCSCs derived from human breast tumors evaluated by TaqMan RT-PCR. MiR-100 expression is reported as fold 
changes compared to P1. P1-P4: luminal; P5-P8: basal-like. B, miR-100 expression in basal-like BrCSCs (P5) before and after growth in 
differentiation condition, at the indicated times. Data are representative of two independent experiments.
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Figure 4: MiR-100 affects tumor-initiating ability and inhibits Wnt/β-catenin signaling pathway in BrCSCs. A, in vivo 
growth of BrCSCs expressed as volume of orthotopic tumors generated by fat-pad injection of either wt, scramble or miR-100 expressing 
BrCSCs. Insert: dorsal and ventral whole body in vivo imaging analysis of orthotopic tumor growth. Data are average ± SD of experimental 
groups containing 6 mice. *** P<0.001. B, representative Hematoxylin/Eosin (H&E) and immunohistochemical stainings (Ki67, ALDH1) 
of tumors originated from wt, scramble and miR-100 BrCSCs. Magnification 20x. C, percentage of TOP-GFP positive cells in wt, scramble 
and miR-100 transduced BrCSCs assessed by flow cytometry. As a positive control to monitor β-catenin activity, TOP-GFP reporter 
lentivirus-transduced BrCSCs were treated with Bio (Bio), an inhibitor of GSK-3α/β. D, heat-map showing hierarchical clustering of genes 
in cells transduced as in (A). Gene expression was assessed by using a Wnt target array. E, Percentage of CD10 Max fluorescence intensity 
in scramble or miR-100 expressing BrCSCs, untreated or stimulated either with Wnt3a or DKK1 assessed by flow cytometry. 
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Supplementary Table 1) displaying low levels of miRNAs 
of the miR-100 family (Fig 2A and Supplementary Fig. 
2). These data indicate that miR-100 expression leads to 
the loss of CSC properties such as self-renewal and tumor-
initiating ability.
MiR-100 inhibits the Wnt signaling pathway and 
downregulates Polo-like kinase1 (Plk1)
The Wnt/-βcatenin pathway is among the main 
signalling pathways involved in cancer stem cell 
maintenance. Tumor-initiating cells show a constitutive 
activation of this pathway, which can be evaluated by the 
LEF-1/TCF dGFP reporter [31]. In order to investigate 
whether the Wnt pathway contributes to miR-100 pro-
differentiative program, BrCSCs wild type, scramble and 
miR-100 were transduced with the reporter and analyzed 
by flow cytometry. MiR-100 expressing BrCSCs displayed 
a significant reduction of β-catenin activity (Fig. 4C). 
Through gene array analysis, it was observed that miR-
100 leads to inhibition of the Wnt signaling pathway 
and to downregulation of β-catenin target genes (such 
as WISP1/2, DLK1, TCF4 and SFRP2) that control the 
Figure 5: MiR-100 impairs CSC properties by down-regulating Plk1. A, Western blot analysis of Plk1 expression in wt, 
scramble or miR-100 transduced BrCSCs; a total protein lysate of HeLa cells was used as a positive control. B, colony forming efficiency 
of wt and miR-100 expressing BrCSCs transduced with either an empty vector (mock) or Plk1, assessed by soft agar assay; histogram 
shows the quantitative analysis. Data are average + SD of 3 independent experiments. C, representative fluorescence microscopy images 
of BrCSCs transduced as in (B) and labelled with PKH-26 (upper left). Flow cytometry analysis of PKH-26 in cells transduced as in (B) 
after 14 days of culture (bottom left) and the corresponding quantification (right). D, Analysis of BrCSC mortality in bulk and CD49fhigh/
CD24low sorted BrCSCs upon treatment with the Plk1 inhibitor BI2536 (10nM) for 72 hours. The experiments were performed in triplicates. 
UT: untreated.
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balance between stemness and differentiation (Fig. 4D 
and Supplementary Fig. 5). On the contrary, BMP4, 
which promotes terminal differentiation of CSCs [32], 
was upregulated (Fig. 4D and Supplementary Fig. 5). 
To evaluate if the Wnt pathway is epistatic to miR-100 
in controlling breast cancer stemness, we stimulated 
scramble and miR-100 transduced BrCSCs and evaluated 
the expression of the stem cell marker CD10. As shown 
in Figure 4E, in control cells Wnt3a stimulation increased 
the expression of CD10, whereas this effect was no longer 
visible in cells expressing miR-100. Altogether, these 
data infer that miR-100 expression interferes with CSC 
maintenance, acting downstream to the Wnt pathway, and 
triggers the activation of a differentiation program. 
In an attempt to untangle the molecular mechanisms 
underlying miR-100 induced phenotype, the expression 
of Plk1, a known miR-100 target gene recently shown 
to be involved in the regulation of stem cell proliferation 
Figure 6: Ectopic expression of miR-100 reduces stem cell markers and induces markers of differentiation. Flow 
cytometry analysis of CD44, CD24, CD10, CD49f and EpCAM expression in BRCSCs (P5) scramble and stably expressing miR-100. 
IMC: Isotype Matched Control.
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and differentiation [33, 34], was analyzed. MiR-100 
transduced BrCSCs displayed a significant reduction 
of Plk1 protein (Fig. 5A). Rescue experiments were 
performed by re-introducing Plk1 in miR-100 expressing 
BrCSCs and evaluating their self-renewing ability. 
Upon Plk1 expression, colony forming efficiency was 
partially recovered (Fig. 5B), while self-renewal was 
restored at a level comparable to wild type BrCSCs (Fig. 
5C). Consistently, the Plk1 inhibitor BI2536 impaired 
viability both in the bulk population of BrCSCs and in 
the CD49fhigh/CD24low sorted cells (Fig. 5D). These results 
indicate that Plk1 plays a key role in mediating miR-100 
induced phenotype. 
SMARCA5 and SMARCD1, two miR-100 targets 
belonging to the SWI/SNF protein family, have recently 
been shown to participate in differentiation of embryonal 
[24, 35] and cancer stem cells [36]. When we analyzed 
their expression, we found that these two proteins were 
significantly down-regulated in miR-100 transduced 
BrCSCs compared to controls (Supplementary Fig. 6A, 
B), suggesting that SMARC, together with Plk1, reduction 
could contribute to miR-100 dependent differentiation.
Figure 7: Ectopic expression of miR-100 reduces stem cell markers, promotes luminal differentiation and renders 
basal-like BrCSCs responsive to endocrine therapy. A, representative confocal microscopy images of immunofluorescence (IF) 
analysis of ALDH1, Cytokeratins (CK5, CK14, CK8-18) and estrogen receptor (ER) performed in BrCSCs (P5) wt and stably expressing 
either a control scramble or miR-100. Nuclei were counterstained by Toto-3 (blue). Magnification 40x. B, quantification of the IF staining 
shown in (A), performed in three independent replicates. ** P<0.01 *** P<0.001. C, representative FACS analysis of Aldefluor assay 
performed in wt, scramble and miR-100 BrCSCs. Cells were exposed to Aldefluor substrate (BAAA); cells treated with the specific inhibitor 
of ALDH1 (DEAB) are shown in the insert panels and were used to define the population with low and high (gated region) ALDH1 activity. 
D, representative analysis of ER-dependent transcriptional activity. The assay was performed in wt, scramble and miR-100 BrCSCs, non 
transfected (negative control) or transfected (ERE-reporter) with a construct where an Estrogen Responsive Element (ERE) containing 
promoter drives luciferase expression. Luciferase activity was evaluated in the absence or in the presence of 10nM 17-β-estradiol (E2). 
MCF7 cells were used as positive control of response to estradiol. E, Analysis of BrCSC viability upon treatment with tamoxifen (tam) and 
fulvestrant (fulv) at the indicated doses. The experiments were performed in triplicates. ** P<0.01.
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MiR-100 promotes luminal differentiation 
and renders basal-like BrCSCs responsive to 
hormonal therapy
To further validate the role of miR-100 in 
controlling stemness and differentiation of breast 
cancer cells, we evaluated either by flow cytometry or 
immunofluorescence (IF) the expression of putative 
stem/progenitor and differentiation markers upon ectopic 
expression of the miRNA. FACS analysis showed that 
stem cell markers, such as CD44, CD10 and CD49f, were 
drastically reduced, while the differentiation markers 
CD24 and EpCAM increased (Fig. 6). We also assessed 
the expression of additional mammary stem/progenitor 
markers by immunofluorescence analysis. Early 
progenitor/stemness markers such as ALDH1, Cytokeratin 
5 and myoepithelial Cytokeratin 14 were reduced in miR-
100 transduced BrCSCs; conversely, the luminal epithelial 
markers Cytokeratin 8-18 and ER were de novo expressed 
(Fig. 7A, B and Supplementary Fig. 7A, B). Expression 
of ER upon miR-100 transduction was confirmed by 
FACS analysis as well (Supplementary Fig. 8A). Using 
the Aldefluor assay, we found that ALDH1 activity was 
also greatly reduced (Fig. 7C and Supplementary Fig. 
7C). Furthermore, the luminal differentiation promoted 
by miR-100 was observed in CD49fhigh/CD24low sorted 
BrCSCs as well (Supplementary Fig. 8B), confirming that 
miR-100 not only interferes with stemness maintenance, 
but also converts the breast cancer phenotype from basal 
to luminal-like. 
Then, we wondered whether the ER pathway was 
functional in miR-100 expressing BrCSCs. Indeed, cells 
transfected with an ERE luciferase reporter displayed 
an increased luciferase activity in the presence of miR-
100 compared to control cells (Figure 7D). Finally, we 
investigated whether miR-100 expression could sensitize 
basal-like unresponsive BrCSCs to ER inhibitors. 
Viability of miR-100 transduced P5 and P8 BrCSCs was 
significantly affected by tamoxifen and fulvestrant, at 
concentrations comparable to those used as optimal dose 
regimen for the treatment of hormone receptor positive 
breast cancers (Fig. 7E and Supplementary Fig. 7D). 
These findings indicate that the differentiation program 
activated by miR-100 is able to induce ER expression and 
to sensitize basal-like BrCSCs to endocrine therapies.
Low miR-100 expression predicts poor prognosis 
in breast cancer patients 
To understand the clinical relevance of miR-100 as 
a possible prognostic factor, we examined its expression 
in 123 breast tumor specimens. Patients underwent radical 
local-regional therapy for resectable node-negative breast 
cancer and received no further adjuvant treatments until 
relapse (Supplementary Table 2). Patients were categorized 
according to tertiles of miR-100 expression. At a median 
follow-up of 60 months, low miR-100 expression was 
associated with worse distant metastasis-free survival 
in the whole population and in the subgroup with ER-
positive tumors (Fig. 8A). To confirm the prognostic 
value of miR-100, a univariate Kaplan-Meier analysis was 
conducted on two validation sets of breast cancer patients 
who underwent surgery and received adjuvant treatments 
(GEO dataset superSeries GSE22220 and Supplementary 
Table 3). MiR-100 expression could stratify patients 
according to different prognosis (Supplementary Fig. 9) 
in these case series, as well. Moreover, as highlighted 
by Gene Set Enrichment Analysis (GSEA), miR-100 
positively correlated with genes expressed in luminal 
tumors. On the other hand, low levels of the miRNA were 
associated with gene signatures of high-grade, poorly 
differentiated cancers (Fig. 8B). This confirms that low 
miR-100 expression is related to a more undifferentiated 
phenotype.
DISCUSSION
Studies performed over the past years have 
strengthened the hypothesis that breast tumors originate 
from mammary stem cells, as a consequence of 
dysregulation in the usually tightly controlled process of 
self-renewal. Despite the fact that these CSCs represent 
a small percentage of the tumor mass, growing evidence 
points to them as being the cells responsible for the life-
threatening terminal evolution of the disease. They are 
resistant to conventional therapies and can escape anti-
cancer treatments, giving rise to relapse in patients [3, 
4, 37]. Therefore, untangling the molecular mechanisms 
underlying CSC maintenance becomes a priority for the 
development of new cancer therapies able to eradicate the 
disease. 
It is known that miRNAs contribute in sustaining 
stemness of embryonic stem cells, since ESC maintenance 
is hampered by deficiency in the miRNA processing [14]. 
At the same time, miRNAs are essential regulators of 
ESC differentiation, which is associated with changes 
in the expression of specific miRNA patterns [38]. An 
important role of miRNAs in controlling self-renewal and 
differentiation of cancer stem cells has also recently been 
described [15, 39, 40]. 
Breast cancer is a heterogeneous disease which 
includes distinct types of tumors characterized by different 
histological origins, molecular features and prognosis 
[41]. Luminal tumors are characterized at the molecular 
level by the expression of ER and PR receptors. ER and 
PR signaling sustains tumor growth and thus, therapies 
interfering with ER activation are currently the gold 
standard for the treatment of this type of cancer. Basal-
like tumors are defined by their lack of ER, PR and HER2 
expression in about 75% of cases. These cancers are 
poorly differentiated and are loaded with CSCs, a feature 
87
Oncotarget10www.impactjournals.com/oncotarget
that is associated with a poor clinical outcome [28, 42]. 
The absence of the specific molecular targets in basal-like 
breast cancers renders ineffective the targeted therapies 
that significantly improve prognosis for hormone receptor-
positive and HER2-overexpressing breast cancers. 
Therefore, a possible therapeutic strategy to treat basal-
like tumors is to induce CSC differentiation and to allow 
the expression of genes, such as ER, to be used as targets. 
The strategy of using drugs that force malignant cells to 
terminally differentiate has been known for the past thirty 
years as “differentiation therapy” and is strictly connected 
to the concept of tissue-selective therapy (43). Such an 
approach drastically reduces side effects in patients 
since it avoids indiscriminately killing proliferating cells 
and instead concentrates its efficacy on cancer cells in a 
tissue specific manner, taking advantage of differentiation 
molecules that are specifically expressed in the selected 
tissue. This therapy has its successful paradigm in the 
treatment of acute promyelocytic leukemia (APL) with all-
trans retinoic acid [44]. However, despite the promising 
results obtained in hematological malignancies, the 
application of differentiation therapy in solid tumors 
has been hampered due to inadequate knowledge of 
the mechanisms governing cell differentiation. The 
Figure 8: Low expression of miR-100 correlates with poor prognosis and high grade tumor signatures in breast cancer 
patients. A, Kaplan-Meier curves associated to miR-100 expression in a cohort of 123 breast cancer patients (for characteristics of patients 
see Supplementary Table 2). Left panel: all patients; right panel: estrogen receptor-positive patients. B, miR-100 expression was correlated 
with gene expression data and gene set enrichment analysis was performed on ranked genes. Two of the top positively (left) or negatively 
(right) correlated gene sets are reported.
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current findings uncover miR-100 as a key player in the 
complex scenario of the differentiation process. They 
show that miR-100 is critical in controlling stemness and 
differentiation of patient-derived basal-like breast CSCs. 
MiR-100 interferes with the CSC properties, impairing 
self-renewal and blocking tumor-initiating ability. 
Our results also suggest that miR-100 induces a pro-
differentiative program which involves the Wnt/β-catenin 
pathway. Activation of β-catenin and expression of Wnt 
target genes are involved in the balance between stemness 
and differentiation. Indeed, it was found that Wnt pathway 
activation was reduced in cells expressing miR-100 and 
Wnt3a treatment was unable to promote the expression of 
stem cell markers. Moreover, the down-regulation of Plk1, 
a serine/threonine kinase target of miR-100 that controls 
cell cycle progression, was observed. Recently, Plk1 has 
been implicated in the regulation of stem cell maintenance 
and proliferation, as inhibiting Plk1 activity impaired 
growth and induced apoptosis of neurospheres [34] and 
of colon cancer initiating cells [33]. Here it was shown 
that Plk1 is required to sustain expansion of BrCSCs, as 
miR-100 mediated down-regulation of Plk1impairs CSC 
properties and depletes the CSC pool. 
Furthermore data from this research provide 
evidence that the exogenous expression of this miRNA 
not only hampers the replication potential of basal-like 
BrCSCs, but also induces their differentiation toward 
a luminal phenotype. In this way, miR-100 allows the 
conversion of an aggressive molecular subtype of cancer 
into a subtype with a better prognosis, for which effective 
treatments are available. Indeed, miR-100 promoted 
the expression of the estrogen receptor and rendered 
basal-like cells responsive to 17-β-estradiol and to the 
anti-proliferative activity of tamoxifen and fulvestrant. 
Several miRNAs (such as miR-206, miR-221/222, miR-
22, miR-17/92 and miR-145) inhibit ER expression and 
sustain resistance to hormonal therapies [45-47]. However, 
miRNAs that are able to induce de novo expression of this 
target molecule and responsiveness to endocrine treatment 
in triple negative breast cancer cells have never been 
previously described. 
The results obtained in this pre-clinical system are 
consistent with the analysis performed on breast tumor 
specimens. High levels of miR-100 are associated with 
luminal gene signatures, while undifferentiated high 
grade tumors correlate with lower miRNA expression. 
This is also in line with recent findings that demonstrate 
the presence of a higher CSC content in G3 poorly 
differentiated tumors [30]. This could explain the poor 
outcome and the tendency to relapse [28]. Moreover, the 
analysis of breast tumor specimens from two validation 
data sets, which include patients who received adjuvant 
therapy, revealed that low expression of miR-100 
correlates with a negative prognosis in ER-positive 
patients. This raises the question as to whether this miRNA 
might be a predictor of hormonal therapy response. Further 
studies on appropriate cohorts of patients are warranted to 
address this hypothesis. 
Overall, these findings have relevant clinical 
implications, as they suggest the possibility of targeting 
basal-like CSCs using a pro-differentiative therapy 
approach, by promoting miR-100 expression. Moreover, 
they propose miR-100 as a response predictor to endocrine 
therapy and offer a therapeutic perspective in treating an 
aggressive tumor type, for which there are no effective 
therapeutic options available at this time.
METHODS
Tissue collection and cell culture 
Fresh tissue acquired from mastectomies of 8 
patients (age 40–89) were collected at the University 
of Palermo and Fondazione IRCCS INT of Milan, in 
accordance with ethical standards. Breast tumor cells 
were purified from fresh tissue via enzymatic digestion 
as previously described [48]. Thereafter, single cell 
suspensions were plated in ultra-low attachment flasks 
(Corning) at a density of 1×105/ml and grown in a medium 
supplemented with bFGF (10 ng/ml, Sigma) and EGF 
(20 ng/ml, Sigma). To induce differentiation, cells were 
cultured in adherent conditions in Ham’s/F-12 medium 
(Euroclone), supplemented with 5% fetal bovine serum 
(FBS), insulin (25μg/ml, Sigma) and hydrocortisone (1mg/
ml, Sigma). MCF7 cells were purchased from ATCC and 
cultured in DMEM supplemented with 10% fetal bovine 
serum (Sigma). 
Cell transfection, lentiviral constructs and cell 
transduction
MCF7 cells were transiently transfected with a miR-
100 specific antagomir (AM10188, Ambion) in serum free 
medium using Lipofectamine 2000 (Invitrogen). MiR-100 
stable expression was obtained by transducing cells with 
a lentivirus expressing miR-100 as previously described 
[26]. The lentiviral short hairpin scramble (pLKO.1) 
used as a control was purchased from Sigma. For the 
in vivo imaging, gene transfer was performed using a 
TWEEN lentiviral vector containing luciferase (LUC) 
and green fluorescent protein (GFP) as reporter genes. For 
β-catenin activity assay, BRCSCs were transduced with 
lentiviral-TOP-dGFP-reporter (Addgene) that consists of 
a LEF-1/TCF-responsive promoter upstream d2-eGFP. 
Transfection of packaging cell line HEK-293T was 
performed using FuGENE Reagent (Roche) and following 
the manufacturer’s instructions. BRCSCs were dissociated 
into single cells, then infected with 100 ng virus/105 cells.
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Biological assays
For the clonogenic assay, cells were plated on a 
ultra-low adhesion 96-well plate at a concentration of 
a single cell per well and observed for 21 days. Wells 
containing either none or more than one cell were 
excluded from the analysis. For soft agar assay, 0.4% 
Seaplaque soft agar (Lonza) was diluted with stem cell 
medium and was covered by a second 0.3% soft agar layer 
in which BrCSCs were embedded. After 21 days, colonies 
were stained with 0.005% crystal violet (Sigma) for 1 hour 
at 37°C. For anti-estrogen treatment, cells were treated 
with 2.5-10 μM tamoxifen (Selleckchem) and 0.5-2 μM 
fulvestrant (Selleckchem) for 24-48 hours. Cell viability 
was assessed by means of a cell Titer Aqueous Assay Kit 
(Promega) following the manufacturer’s instructions. 
Alternatively, cell death was evaluated by orange acridine/
ethidium bromide staining as previously described [48] 
and using Cell Titer-Glo luminescent cell viability assay 
kit (Promega). For the assessment of apoptosis, 3x103 
cells/well were seeded in ultra-low adhesion 96-well 
plate in stem cell medium and activation of caspases 3 
and 7 was evaluated after 72hours using the Caspase-
Glo 3/7 Assay (Promega). The proliferative rate of stem 
cells was analyzed using the PKH-26 assay (2×10-6 M, 
Sigma) according to manufacturer’s instructions. Samples 
were analyzed by FACSCalibur (BD Biosciences). For 
β-catenin activity experiments, cells transduced with the 
indicated lentiviral constructs were analyzed by FACS. 
As a positive control, cells were treated with BIO (1uM, 
Calbiochem) for 24 hours in order to inhibit GSK-3α/β. 
For viability assay, single cells suspensions were treated 
with the Plk1 inhibitor BI2536 (10nM, Selleckchem) for 
72 hours.
In order to evaluate changes of CD10 expression 
upon Wnt pathway modulation, scramble or miR-100 
BrCSCs were treated either with Wnt3a (300ng /ml) every 
6 hours for 24 hours or DKK1 (200ng/ml) for 24 hours 
and then analyzed by flow cytometry.
FACS analysis and Cell sorting
BrCSCs were exposed to primary antibodies CD44 
(BU75, Ancell), CD24 (ML5, R&D System), CD10 
(FR4D11, Santa Cruz Biotechnology), CD49f (GoH3 
Miltenyi Biotec), EpCAM (AF960, R&D System) or 
corresponding isotype controls, rinsed and labeled with 
secondary antibodies. BrCSCs were stained with CD49f 
and CD24 and successively sorted via flow cytometry 
using an FACSAria cell sorter (BD Biosciences). The 
analysis of ALDH1 activity was performed using the 
ALDEFLUOR kit (StemCell Technologies). For cell cycle 
analysis, BrCSCs were fixed in 70% ethanol and incubated 
with 50 μg/mL propidium iodide (Sigma-Aldrich), 3.8 
mmol/L sodium citrate (Sigma) and 10 μg/mL RNase 
(Sigma). Samples were analyzed by FACSCalibur and 
CellQuest Software (BD Biosciences). 
Quantitative analysis of microRNA and gene 
expression
Total RNA was extracted using TRI Reagent 
solution (Ambion) following manufacturer’s instructions. 
Analysis of miR-100, miR-99a and miR-99b was 
performed starting from equal amounts of total RNA/
sample (10ng) using the specific Taqman microRNA 
assay kits (Applied Biosystems). MiRNA expression was 
calculated as fold change using the delta-delta CT method 
and RNU48 as endogenous control.
Gene expression was evaluated by quantitative real-
time PCR using the EXPRESS SYBR green (Invitrogen). 
Retrotranscription was performed using the High Capacity 
Retrotranscription Kit (Applied Biosystems) starting from 
500ng of total RNA.
Expression profiling of pluripotency genes was 
performed starting from 1.5ug of total RNA using 
TaqMan Human Stem Cell Pluripotency Arrays (Applied 
Biosystems), according to manufacturer’s instructions. 
Gene expression was calculated as ∆CT (CT gene - CT 
GAPDH). The differentially expressed genes were 
statistically analyzed using t-test and genes with a P<0.05 
were included in the heat-map. Expression was reported 
as -∆CT normalized to the median. The heat-map was 
obtained by Gedas software [49].
Expression of Wnt target genes was performed 
through RT2 profiler PCR array (PAHS-243, Qiagen), 
according to manufacturers’ instructions. Arrays were 
performed independently for BrCSCs wt, scamble and 
miR-100 and at least 3 technical replicates were run for 
each sample. Cycle threshold values were normalized 
using the average of 5 housekeeping genes on the same 
array (B2M, HPRT1, RPL13A, GAPDH and actin B). The 
comparative cycle threshold method was used to calculate 
the relative quantification of gene expression.
Animal models
Orthotopic xenografts were obtained by injecting 
105 BrCSCs P5 or P8 in the murine mammary gland of 
three week-old female NOD/SCID mice. In vivo imaging 
was performed by a Biospace instrument upon i.p. 
injection of Luciferin (150 mg/kg, Promega). 
Immunohistochemistry
Immunohistochemistry was performed on paraffin-
embedded sections and labelled with Ki67 (MIB-1, Dako) 
and ALDH1 (44, BD Biosciences). Immunocomplexes 
were revealed by peroxidase labeled streptavidin following 
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manufacturer’s instructions (LSAB2, Dako). Stainings 
were revealed using AEC (Dako) and counterstained with 
aqueous hematoxylin. 
Immunofluorescence
BrCSCs were fixed with 2% paraformaldehyde 
for 30 minutes at 37°C and incubated O.N. at 4°C with 
the following primary antibodies: ALDH1 (44, BD), 
CK5 (XM26, Novocastra), CK14 (LL002, Novocastra), 
CK8-18 (CD10, Novocastra), MUC1 (BD Pharmigen), 
VIMENTIN (R28, Cell Signaling), ER (6F11, 
Novocastra). Thereafter, cells were labeled with secondary 
antibodies (Invitrogen). Nuclei were counterstained with 
Toto-3 (Invitrogen).
Western blot
Cell pellets were lysed in buffer (TPER, Pierce; 300 
mM NaCl; 1 mM orthovanadate; 200 mM PEFABLOC, 
Roche; 5 µg/ml Aprotinin, 5 µg/ml Pepstatin A, 5 µg/ml 
Leupeptin, Sigma). Lysates (30 µg/lane) were fractioned 
with SDS-PAGE and blotted to PVDF. Membranes were 
blocked with no-fat dry milk in TBS 0.05% Tween20 and 
incubated overnight with a specific antibody for Plk1 
(208G4, Cell Signaling), SMARCD1 (AB81621, Abcam), 
SMARCA5 (MAB120, Millipore) and β-actin (JLA20, 
Calbiochem). Densitometric analysis was performed by 
UVP. 
ERE-reporter assay
Cells were transfected with 1μg mixture of an 
inducible ERE-responsive firefly luciferase construct 
(kindly provided by Dr. De Bortoli, University of 
Torino) and a constitutively expressing Renilla luciferase 
construct (40:1) (Cignal Reporter Assay, Qiagen) using 
Lipofectamine 3000 reagent (Life Technologies) according 
to the manufacturer’s instructions. Cells were seeded into 
ultra-low attachment 24 wells plates (Corning) at a density 
of 100,000 cells per well. After 48 hours from transfection, 
cells were treated for 6 hours with either vehicle or 10 nM 
17-β-Estradiol (E2758, Sigma) and the reporter activity 
was measured by luminescence. Values were normalized 
to Renilla luciferase activity; data are presented as relative 
luciferase values. 
Case series at INT 
The case series collected at INT in Milan consisted 
of 123 patients with primary invasive breast cancer and 
negative lymph nodes. They were subjected to radical and/
or conservative surgery, plus radiotherapy. These patients, 
recruited from 1990 to 1998, were identified among 
those who developed distant metastasis within 5 years of 
treatment (59 patients, disease free survival range: 8-58 
months) and those who were disease-free for more than 
60 months (64 patients, disease free survival range: 60-
185 months). The two subsets of patients were comparable 
in age, tumor size, histotype, ER and HER2 status. Each 
patient wrote an informed consent, which authorized 
the use of material for research purposes. The study was 
approved by the Independent Ethics Committee and the 
Institutional Review Board. 
miRNA and gene expression analysis in breast 
cancer patients
Global gene and miRNA expression data were 
obtained using the HumanRef-6_v3 and Human miRNA_
V2 Illumina BeadChips, respectively. Raw data were 
generated using the Illumina BeadStudio 3.8 software and 
processed using the Bioconductor lumi package. After 
quality control, the Robust Spline Normalization was 
applied. For gene signature expression analysis, all genes 
were correlated with miR-100 expression and gene sets 
from the C2 collection of the MSigDB were tested for 
their enrichment among positively or negatively correlated 
genes using GSEA (http://www.broadinstitute.org/gsea).
Statistical analysis
Data were expressed as average ± standard 
deviation. Statistical significance was determined by the 
t-test or by Analysis of Variance (one-way or two-way) 
with Bonferroni post-test. P values <0.05 were considered 
significant (* P<0.05; ** P<0.01; *** P<0.001).
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MATERIALS AND METHODS 
 
 
Validation case series (cohort II) 
 
58 frozen primary invasive  ductal breast cancer specimens,  obtained  from patients who underwent 
primary surgical treatment between 1988 and 2001 at a median age of 54 years (25-82), were selected from 
the Tumor Bank of the Department of Obstetrics and Gynecology, University of Turin. Eligibility criteria 
were the following: diagnosis of  invasive  breast  cancer,  all  T  and  N  stage,  no  distant  metastasis  at  
diagnosis, complete clinical-pathological data and updated follow up for at least 72 months and up to 100 
months. All patients were treated with radical modified mastectomy or quadrantectomy   and  axillary  
dissection  plus  breast  irradiation.  High-risk  node- negative and node-positive patients received adjuvant 
treatments (generally 6 cycles of CMF, 600 mg/m2 cyclophosphamide, 40 mg/m2 Metotrexate, 600 mg/m2 
5- Fluorouracil)  and/or 20 mg tamoxifen  daily for 5 years in ER+ cases. ER and PR status was 
determined  by immunohistochemical  stainings, patient stage distribution was assessed as prescribed by the 
UICC clinical staging guidelines and tumor grading was performed according to Elston and Ellis. 
 
Reference List 
 
1.   Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H et al. microRNA-associated 
progression pathways and potential therapeutic targets identified by integrated mRNA and 
microRNA expression profiling in breast cancer. Cancer Res 2011;71:5635-45. 
 
 
 
 
 
 
 
 
95
 Supplementary Figure 1: MiR-100 expression is lower in mammospheres than in differentiated cells. 
A, phase contrast images of the breast cancer cell lines BT474 and ZR-75-1 grown in adherent conditions 
(adherent) or cultured as spheres in stem cell conditions (spheres). Magnification 4x. B, evaluation of 
miR-100 expression by TaqMan RT-PCR in the cells shown in (A), reported as fold changes compared 
to adherent cells. Results are representative of 2 independent experiments. 
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 Supplementary  Figure  2:  MiR-100  family  member  expression  in  BrCSCs.  A, miR-100,  miR-99a  and  
miR-99b  expression  in  P5  and  P8  BrCSCs  evaluated  by TaqMan RT-PCR and reported as ∆CT  versus RNU48 
endogenous control. B, miR-99a and miR-99b expression in P5 BrCSCs before and after growth in differentiation 
condition  at  the  indicated  times.  Data  are  reported  as  fold  change  compared  to undifferentiated cells (0 days). 
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 Supplementary Figure 3: MiR-100 affects BrCSC maintenance. A, representative FACS analysis and 
cell sorting using the CD49f and CD24 markers performed in BrCSCs.  B,  percentage  of  clonogenicity  in  
bulk  and  CD49fhigh/CD24low    sorted BrCSCs wild type (wt) and stably expressing either a control 
scramble (scr) or miR-100. Data are average + SD of 3 independent experiments. C, analysis of caspase 3/7 
activation performed using the Caspase-Glo  3/7 Assay in BrCSCs transduced as in (B). **P<0.01. 
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 Supplementary Figure 4: MiR-100 affects tumor-initiating ability of BrCSCs. In vivo growth of P8 
B rCSCs expressed as volume of orthotopic tumors generated by fat-pad injection of either wt, scramble or 
miR-100 expressing cells. Data are average ± SD of experimental groups containing 6 mice. 
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Supplementary Figure 5: MiR-100 inhibits the Wnt/β-catenin signaling pathway. Wnt target gene expression 
profiling of wild type and miR-100 expressing BrCSCs. In the table, gene expression levels are reported as fold changes 
between miR-100 expressing and wild type cells. Down-regulated genes are in green, up-regulated genes in red. 
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 Supplementary  Figure 6: MiR-100 downregulates  SMARC proteins in BrCSCs. A, Immunoblotting 
analysis of SMARCA5 and SMARCD1 in wt, scramble or miR-100  expressing  BrCSCs;  control:  total  
lysate  of  HeLa  cells.  B,  Densitometric quantification of protein expression in BrCSCs transduced as in 
A. Data represent the mean ± SD of 2 independent experiments. *P<0.05, **P<0.01. 
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 Supplementary   Figure  7:  Ectopic  expression  of  miR-100  reduces  stem  cell markers and 
promotes luminal differentiation in basal-like BrCSCs. A, confocal microscopy  analysis  of  ALDH1,  
Cytokeratins  (CK5,  CK14,  CK8-18)  and  ER  in patient-derived basal-like BrCSCs (P8), wild type (wt) or 
stably expressing either a control scramble or miR-100. Nuclei were counterstained by Toto-3 (blue). 
Magnification  40x.  B,  quantification  of  the  IF  staining  shown  in  (A).  C,  flow citometry analysis of 
Aldefluor assay performed in P8 BrCSCs transduced as in (A). Cells were exposed  to Aldefluor  substrate  
(BAAA);  cells treated with the specific inhibitor of ALDH1 (DEAB) are shown in the insert panel and 
were used to define the population  with  low  and  high  (gated  region)  ALDH1  activity.  D,  analysis  of  
P8 BrCSC viability upon treatment with tamoxifen (tam) or fulvestrant (fulv) at the indicated doses. *P<0.05, 
**P<0.01, ***P<0.001. 
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 Supplementary Figure 8: Ectopic expression of miR-100 promotes luminal differentiation in 
CD49fhigh/CD24low  BrCSCs. A, FACS analysis of ER expression in bulk BrCSCs wild type (wt) and stably 
expressing either a control scramble (scr) or miR-100. B, representative confocal microscopy images of IF 
analysis of CK8-18, Vimentin, MUC1 and ER performed in CD49fhigh/CD24low  BrCSCs wt and stably 
expressing miR-100. Nuclei were counterstained by Toto-3 (blue). C, quantification of the IF staining 
shown in (B). 
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Supplementary   Figure  9:  Low  expression  of  miR-100  correlates  with  poor prognosis  in two 
validation  cohorts of breast cancer patients.  A, Kaplan-Meier curves   associated   with   miR-100   
expression   in   the   GEO   dataset   superSeries GSE22220   (1).  Left  panel:  all  patients;  right  panel:  
estrogen  receptor-positive patients. B, Kaplan-Meier curves associated with miR-100 expression in a 
cohort of 58 patients (for patients’ characteristics see Supplementary Table 3). Left panel: all patients; right 
panel:  estrogen receptor-positive patients. 
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Conclusions 
Regenerative medicine is a combination of clinical and researching interdisciplinary 
field aimed to repairing and regenerating tissues or organs compromises rather than 
replace them. (Fortier RA 2005). The potential of regenerative medicine are huge and 
therefore it is essential and very important keep to invest in this branch so fruitful and 
capable to find new prospect cures for many diseases. Exploiting regenerative 
medicine could overcome the lack of organs for transplantation. To date there are two 
main strands of therapeutic applications: The first is represented by the regeneration 
of solid tissues with the use of stem cells in order to reconstruct in the laboratory a 
piece of tissue, subsequently implanted in patients with a severe congenital 
malformation (Shahar M 2003 ); the second area concerns the cell therapy of diseases 
which have not a genetic origin and through with the use of well-characterized cell 
populations, subjected to particular treatments, such as the selection cell, in vitro 
expansion, the generation of clones anti-infective and anti-neoplastic (Piscaglia 
AC2008). This goal can be achieved by identifying a capable cell source for the 
regenerating damaged tissue and building a microenvironment more suitable to house 
and instruct cells. A source cell can be considered ideal when it is available, 
expandable in vitro, multipotent and able to regenerate a functional mature tissue in 
vivo without neoplastic transformation risk. Stem cells are those which are closest to 
this model. They found in all organisms, are undifferentiated cells capable of self-
renewal and that  playing a central role in homeostasis, rise new different mature 
progenies in order to increase tissue mass during growth or or to replace tissues due 
to aging or damage.Stem cells possess a hierarchical organization: from totipotent 
zygote, the pluripotency of embryonic stem cells (ESCs), to multipotency of adult 
stem cells. One promising adult stem type for regenerative medicine is the 
mesenchymal stem cells. Thanks to their particular characteristics MSCs are now 
considered as the most promising candidate for regenerative medicine and tissue 
engineering. The main characteristics of MSCs were first described in bone marrow 
tissue, but over the last 15 years,  however, the attention  was focused on finding an 
abundant valuable alternative multi-potent stem cells MSCs source that could be 
isolated from other tissues. Within the white adipose tissue, there is a presence of 
mesenchymal stem cells that are associated with potent intrinsic peculiarities.  
Adipose tissue mesenchymal stem cells can differentiate into a variety of cell lines 
and for these reasons the adipose tissue is considered an ideal MSCs source in 
association with therapeutic needs and in particular for the repair of defects in the 
regenerative medicine. Spheroids derived from human adipose tissue “ASphCs” are 
enriched with mesenchymal stem cells, endowed with the capability of multilineage 
differentiation and repairing bone injury. ASphCs  showed intrinsic stem cell 
properties, infact despite they are quiescent, once they are forced to differentiate, they 
up-regulate the specific gene regulators that govern the maturation in the three 
different mesenchymal lineages in a more significant and higher than the commercial 
Adipose Derived Stem Cells, which are in our opinion non-clonogenic progenitors, 
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poorly able to form floating spheroids and  to sustain in vitro serial passages. So it is 
likely that ASphCs and ADSCs may reside at different levels of the stemness 
hierarchy.  Moreover mesenchymal stem cells have been widely used in  in vivo 
experimental models related to the treatment of bone diseases. In this study, we have 
seen that Adipose stem cells were able to directly participate in bone tissue 
regeneration but supports that only spheroids derived from human adipose tissue 
“ASphCs” that expresses  high levels CD271, possesses an higher in vivo 
multipotency, harbours the capacity to repair bone injury and could be exploited in 
regenerative medicine. (Chapter 1).  
Breast carcinoma represents the most common neoplasia in women responsible for 
over 400,000 deaths every year. The individual risk is indeed influenced by many 
different factors such as family history, age, lifestyle and environment. The breast 
carcinomas classification for many decades was done on the histologic type and grade 
basis, The most common breast cancer type  is the epithelial lesion, and the most 
frequent histotypes are ductal carcinoma and lobular that. The two histotypes may be 
"in situ", that is non-invasive, or "infiltrating". When cancer cells  beyond the surface 
epithelium and spread within the underlying tissues through the lymph vessels and 
blood we talk about invasive tumor and the most common is ductal histology 
Together with the histological characterization, there is a sub molecular classification 
on the basis of gene expression and identified five subtypes of breast cancer: luminal 
A, luminal B, HER2-enriched, basal-like and claudin-low. In recent years the views 
of the scientific community on cancer biology has drastically changed. The Nowell 
stochastic model, not having an good explanation for the failure of current cancer 
therapies designed to kill proliferating cells, has been replaced by a different model of 
carcinogenesis '' hierarchical '' according to which a tumor would originate from a 
small portion of cells called '' cancer stem cells ''. On the basis of this model the tumor 
mass it is composed by a numerous proliferating cells and a small stem cells 
population responsible of neoplastic growth and progression in the long time. CSC 
model, moreover  justifies how a small fraction cell is necessary and sufficient for the 
recapitulation of the tumor. The main problem in CSC research is the identification 
and characterization of this stem cell subset. The stem cell markers identification  is 
an open scientific debate. Some markers currently used to enrich the population of 
cancer stem cells are CD133 for glioblastoma, colon, lung and prostate; and CD44, 
CD24 for the pancreas, ovary, head and breast. For this reason the molecular targeting 
of such highly tumorigenic cells becomes fundamental to improve the efficacy of 
current anti-cancer strategies. CSC state is increasingly being seen as a flexible, infact 
the tumor present a i heterogeneity (ITH) that may contribute to some of the 
difficulties in validating biomarkers for clinical use, despite the continued discovery 
of potential novel biomarkers. CSCs are indeed used nowadays as a marker of tumour 
aggressiveness and drug resistance, the CSC number and phenotype is also used by 
clinicians to decide the best treatment to apply. [23]. Al-Hajj and colleagues in 2002  
identified by flow cytometric sorting the BCSCs '' cells initiators breast cancer''  
based on the expression of surface antigens such as CD44, CD24, ESA, and others 
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additional markers were used for the characterization of these cells as CD133, 
ALDH1 (Ginestier and colleagues in 2007) For which cells CD44 + CD24- and 
ALDH 1, possess tumorigenic capacity, being able to generate tumor in 
immunocompromised mice since the inoculation of 20 cells. In the same study it was 
also shown that cells CD44 +, CD24- and ESA + would generate cells CD44 + and 
CD24- additional, confirming the theory of asymmetric cell division, maintaining the 
characteristics of self-renewal and the generation of a population heterogeneous cell 
also not tumorigenic that constitute the so-called tumor mass. Recent work by Pitch 
and colleagues of  2010 Another method for the isolation and purification of stem cell 
component from mammosfere cancer, used fluorescent dye PKH-26 FACS analysis 
(Fluorescence Activated Cell Sorter). In accordance with the fluorescence intensity it 
is then possible to select a population PKH-26 
+
 '' stem-like '' (high intensity of dye) 
and a population PKH-26 
-
 '' dividing cells '' (low intensity of dye ). According to this 
profile is therefore possible to predict the biological and molecular characteristics of 
different mammary carcinoma: poorly differentiated or well differentiated. (Chapter 
2) 
Mastectomy is often the only possible therapy against breast cancer. and and often the 
surgeons to overcome the trauma of surgical mutilation suggest patients lipofilling to 
the implant prosthesis. This surgical techniques has been considered safe or very low 
risk untill the American society of plastic and recostrutive  surgeons began to raise 
doubts about the safecty of these. The close correlation between obesity and cancer 
disease, highlighted in the past 20 years, it has raised concerns about a possible 
detrimental interplay. It is known that obesity is associated with a generalized 
inflammation, an elevated  inflammatory cytokines expression  and  macrophages 
recruitment and endothelial dysfunction . Moreover studies on inflammatory cells 
infiltrating the adipose tissue, highlight that these cells generate a specific 
environment that perpetuates the inflammation within tissues and activate adipocytes 
to produce others inflammatory mediators and adipocytokines. Thus it is well 
established the strong correlation between the tumor and its microenvironment we 
suppose that latter plays a critical role in the development and metastasis cancers and 
that lipotransfer could represents a real potential risk for all mastectomy patients that 
undergo to lipofilling. In particular we think that the action of the medium released 
from adipose auotolo filler implanted within the lipotransfer  site can induce an 
awakening of breast cancer stem cells still present and undetectable . Our study 
investigates on a specific adipose stem population, adipose cell spheres, isolated from 
lipoaspirati samples, considered as the true adipose stem cells, present in a quiescent 
state but with a great multi differentiation potential and which we think could be a 
viable alternative to traditional autologous lipofiller. Then through co cultures 
experiments between breast cancer stem cells and adipose stem cells or mature 
adipocytes, we investigated the effect that microenvironment generated from adipose 
tissue stem cell  act on cancer of the breast. The results obtained say that the 
microenvironment generated by adipose cells spheres, although in a less concentrated 
than mature adipocyte and undigested adipose tissue,  is pro-inflammatory, 
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angiogenic and proliferative. Breast cancer stem cells exposed to adipose conditioned 
medium increases the proliferative rate, invasive and migratory capability. In 
addition, breast cancer stem cell treated with adipose conditioned medium switch 
from a luminal to basal phenotype. Finally, our best advice for all breast carcinoma 
woman patients that are forced to demolitive surgery, is the use of others fillers such 
as the alloplastic fillers, some scaffolds or any other implants that could be less inert 
than autologous fillers. (Chapter 3). 
Through a detailed preliminary study we looked for some regulatory mechanism to be 
exploited for the modulation of a specific stem cell population, such as that of adipose 
tissue 
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